<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Nat Rev Mater</journal-id><journal-id journal-id-type="iso-abbrev">Nat Rev Mater</journal-id><journal-id journal-id-type="pmc-domain-id">3814</journal-id><journal-id journal-id-type="pmc-domain">phenaturepg</journal-id><journal-title-group><journal-title>Nature Reviews. Materials</journal-title></journal-title-group><issn pub-type="epub">2058-8437</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer Nature - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8647509</article-id><article-id pub-id-type="pmcid-ver">PMC8647509.1</article-id><article-id pub-id-type="pmcaid">8647509</article-id><article-id pub-id-type="pmcaiid">8647509</article-id><article-id pub-id-type="pmid">34900343</article-id><article-id pub-id-type="doi">10.1038/s41578-021-00399-5</article-id><article-id pub-id-type="publisher-id">399</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Integrating plant molecular farming and materials research for next-generation vaccines</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6578-8076</contrib-id><name name-style="western"><surname>Chung</surname><given-names initials="YH">Young Hun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Church</surname><given-names initials="D">Derek</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7260-9507</contrib-id><name name-style="western"><surname>Koellhoffer</surname><given-names initials="EC">Edward C.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Osota</surname><given-names initials="E">Elizabeth</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shukla</surname><given-names initials="S">Sourabh</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Rybicki</surname><given-names initials="EP">Edward P.</given-names></name><address><email>ed.rybicki@uct.ac.za</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Pokorski</surname><given-names initials="JK">Jonathan K.</given-names></name><address><email>jpokorski@ucsd.edu</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0130-0481</contrib-id><name name-style="western"><surname>Steinmetz</surname><given-names initials="NF">Nicole F.</given-names></name><address><email>nsteinmetz@ucsd.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.266100.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 4242</institution-id><institution>Department of Bioengineering, </institution><institution>University of California, San Diego, </institution></institution-wrap>La Jolla, CA USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.266100.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 4242</institution-id><institution>Department of Nanoengineering, </institution><institution>University of California, San Diego, </institution></institution-wrap>La Jolla, CA USA </aff><aff id="Aff3"><label>3</label>Department of Radiology, University of California, San Diego Health, La Jolla, CA USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.266100.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 4242</institution-id><institution>Biomedical Science Program, </institution><institution>University of California, San Diego, </institution></institution-wrap>La Jolla, CA USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.7836.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1151</institution-id><institution>Department of Molecular and Cell Biology, </institution><institution>University of Cape Town, </institution></institution-wrap>Cape Town, South Africa </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.266100.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 4242</institution-id><institution>Institute for Materials Discovery and Design, </institution><institution>University of California, San Diego, </institution></institution-wrap>La Jolla, CA USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.266100.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 4242</institution-id><institution>Center for Nano-Immuno Engineering, </institution><institution>University of California, San Diego, </institution></institution-wrap>La Jolla, CA USA </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.266100.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 4242</institution-id><institution>Moores Cancer Center, </institution><institution>University of California, San Diego, </institution></institution-wrap>La Jolla, CA USA </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>12</month><year>2021</year></pub-date><pub-date pub-type="ppub"><year>2022</year></pub-date><volume>7</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">395045</issue-id><fpage>372</fpage><lpage>388</lpage><history><date date-type="accepted"><day>18</day><month>10</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>12</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>06</day><month>12</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-21 16:25:26.393"><day>21</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; Springer Nature Limited 2021</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41578_2021_Article_399.pdf"/><abstract id="Abs1"><p id="Par1">Biologics &#8212; medications derived from a biological source &#8212; are increasingly used as pharmaceuticals, for example, as vaccines. Biologics are usually produced in bacterial, mammalian or insect cells. Alternatively, plant molecular farming, that is, the manufacture of biologics in plant cells, transgenic plants and algae, offers a cheaper and easily adaptable strategy for the production of biologics, in particular, in low-resource settings. In this Review, we discuss current vaccination challenges, such as cold chain requirements, and highlight how plant molecular farming in combination with advanced materials can be applied to address these challenges. The production of plant viruses and virus-based nanotechnologies in plants enables low-cost and regional fabrication of thermostable vaccines. We also highlight key new vaccine delivery technologies, including microneedle patches and material platforms for intranasal and oral delivery. Finally, we provide an outlook of future possibilities for plant molecular farming of next-generation vaccines and biologics.</p></abstract><abstract id="Abs2" abstract-type="web-summary"><p id="Par2">Cold chain requirements, distribution challenges and high costs limit the global rollout of many vaccines. This Review discusses plant molecular farming in combination with advanced materials strategies as a new platform for the local production of thermostable vaccines and other biologics.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Plant biotechnology</kwd><kwd>Plant biotechnology</kwd><kwd>Protein vaccines</kwd><kwd>Vaccines</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2022</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par3">A human analogue of insulin (Humulin) was the first biologic introduced into the market in 1983. Since then, biologics have been increasingly used as pharmaceutical agents, outpacing the market of small-molecule drugs<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> with an estimated market size of around US$400&#8201;billion by 2025 (ref.<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>). Biologics are a class of medications that are derived from a biological source and typically fall into one of four major categories: monoclonal antibodies (mAbs), receptor modulators, enzyme modulators and vaccines<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Vaccines have been crucial in eliminating infectious diseases, such as smallpox<sup><xref ref-type="bibr" rid="CR4">4</xref></sup> and rinderpest in 2011 (ref.<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>), and in eradicating once-deadly diseases, such as diphtheria, measles, polio and rubella, by 99%, with many other diseases, such as mumps, pertussis and tetanus, nearing that stage. In the USA alone, it is estimated that in just one generation of children, 13 different vaccines have prevented up to 20 million diseases and 40,000 deaths, with economic savings of up to US$69&#8201;billion<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. On a global scale, these numbers are much higher; one estimate shows that ten vaccines deployed in 94 low- and middle-income countries led to a US$586&#8201;billion reduction in illness-related costs, and a reduction of up to US$1.53&#8201;trillion when considering additional economic benefits<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>.</p><p id="Par4">Vaccines are usually manufactured using cell-based expression systems, such as mammalian and insect cell lines, bacterial or yeast cultures. Plant molecular farming, that is, using plant cells or plants as expression platforms, is a rapidly emerging alternative, which was originally introduced in 1986 for the production of human growth hormone (HGH) in transgenic tobacco and sunflowers<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. Plant molecular farming is currently used for the production of seasonal influenza vaccines<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> and for Elelyso for Gaucher disease in the USA<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Although plant molecular farming may not replace industrial expression systems, it may have a unique role in the generation of vaccines in low-resource areas, for targeting niche and orphan vaccines, and for the production of virus nanoparticles (VNPs) for vaccine applications<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. Furthermore, the rise of the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has focused research attention on novel approaches to vaccines. Traditional vaccines are either live attenuated (that is, less virulent forms of the original pathogen), inactivated (that is, inactivated pathogen without disease-producing capacity), or recombinant proteins and viral vectors. In addition, the two vaccines that were first granted emergency authorization in the USA for COVID-19 are messenger RNA (mRNA) vaccines delivered in lipid nanoparticles<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>.</p><p id="Par5">In this Review, we discuss challenges in current vaccine development and distribution, such as cold chain disruptions and lack of health-care professionals, which are particularly problematic in low-resource areas. Cold chain requirements pose a general logistical challenge for vaccines, as highlighted by the current rollout of the mRNA-based COVID-19 vaccines<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>, and traditional administration techniques, such as injections, require trained health-care professionals. Here, we investigate how molecular farming and nanotechnology-based strategies could provide an alternative strategy to traditional vaccines, enabling rapid development, effective deployment and safe administration of vaccines.</p></sec><sec id="Sec2"><title>Vaccine technology</title><sec id="Sec3"><title>A brief history of vaccines</title><p id="Par6">The history of modern vaccination began with Edward Jenner&#8217;s &#8216;live attenuated&#8217; smallpox vaccine in the late eighteenth century<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. Nearly a century later, in 1885, Louis Pasteur developed a rabies vaccine by drying the brains of infected rabbits; however, this vaccine was rather unpredictable and often caused serious side effects<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Shortly thereafter it was found that heat or chemical treatment could be used to inactivate bacteria, and vaccines for typhoid (<italic toggle="yes">Salmonella typhi</italic>), plague (<italic toggle="yes">Yersinia pestis</italic>) and cholera (<italic toggle="yes">Vibrio cholerae</italic>) were developed<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. Vaccine production was greatly improved in the 1950s, when the development of cell culture techniques enabled the in vitro production of non-virulent viruses instead of requiring to be isolated from infected animals<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Bacterially expressed hepatitis B surface antigen then became the first vaccine produced by recombinant DNA technology<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>, which laid the foundation for the four major categories of modern vaccines: live attenuated, killed/inactivated whole organisms, subunit and toxoid vaccines (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Since then, new vaccine types have emerged, such as viral vectors and nucleic acid vaccines<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Today, 85 human vaccines and vaccine combinations are on the market.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Vaccine types used in the clinic</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Vaccine type</th><th colspan="1" rowspan="1">Formulation</th><th colspan="1" rowspan="1">Advantages</th><th colspan="1" rowspan="1">Disadvantages</th><th colspan="1" rowspan="1">Example (Brand name; Developer)</th><th colspan="1" rowspan="1">Refs</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Live attenuated</td><td colspan="1" rowspan="1">Weakened live pathogen, usually produced by serial culture</td><td colspan="1" rowspan="1"><p>Long-lasting humoral and cell-mediated immunity</p><p>Lower doses needed than inactivated vaccines</p></td><td colspan="1" rowspan="1"><p>Not given to immunocompromised individuals</p><p>Cold chain requirement</p><p>Possible reversion to a virulent form</p></td><td colspan="1" rowspan="1">Measles, mumps, rubella (M-M-RII; Merck)</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR163">163</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Inactivated</td><td colspan="1" rowspan="1">Pathogen killed by heat or chemical treatment</td><td colspan="1" rowspan="1"><p>Cold chain not required</p><p>Cannot reverse to virulence</p></td><td colspan="1" rowspan="1"><p>Usually, no cell-mediated immunity</p><p>Requires boosters</p><p>Usually, more side effects than live attenuated vaccines</p></td><td colspan="1" rowspan="1">Hepatitis A (Havrix; GlaxoSmithKline (GSK))</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR164">164</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Subunit (protein, polysaccharide)</td><td colspan="1" rowspan="1">Comprised of only the immunostimulatory parts of the pathogen</td><td colspan="1" rowspan="1"><p>Lower risk of side effects than live-attenuated and inactivated vaccines</p><p>Long-lasting immunity</p></td><td colspan="1" rowspan="1"><p>Requires multiple doses</p><p>Requires adjuvant to boost immunogenicity</p></td><td colspan="1" rowspan="1">Hepatitis B (Recombivax; Merck)</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR165">165</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Virus-like particles (VLPs)</td><td colspan="1" rowspan="1">Subunit vaccine that self-assembles into non-infectious and non-replicating VLPs; or subunit vaccines presented on a non-infectious VLP</td><td colspan="1" rowspan="1"><p>Lower risk of side effects than live attenuated vaccines</p><p>Long-lasting immunity</p></td><td colspan="1" rowspan="1"><p>More expensive to produce than traditional (less complex) subunit vaccines</p><p>Requires adjuvant to boost immunogenicity</p></td><td colspan="1" rowspan="1">Human papillomavirus (Gardasil 9; Merck) or SARS-CoV-2 (KBP-201; Kentucky Bioprocessing)</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR166">166</xref>,<xref ref-type="bibr" rid="CR167">167</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Nucleic acid</td><td colspan="1" rowspan="1">mRNA or DNA, coding for the pathogenic antigen</td><td colspan="1" rowspan="1"><p>Induces both humoral and cell-mediated immunity</p><p>Rapid development and production</p><p>Relatively inexpensive compared with traditional vaccines</p></td><td colspan="1" rowspan="1"><p>Limited to protein vaccines</p><p>Requires carrier</p><p>May require adjuvant</p></td><td colspan="1" rowspan="1">Cervical lesions (VGX-3100; Inovio)</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR168">168</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Viral vector</td><td colspan="1" rowspan="1">Incorporation of the DNA of an antigen within an attenuated or replication-incompetent virus</td><td colspan="1" rowspan="1"><p>Induces both humoral and cell-mediated immunity</p><p>Wide tissue tropism</p></td><td colspan="1" rowspan="1"><p>Pre-existing immunity</p><p>Possible reversion to virulence, although highly unlikely if replication-incompetent</p></td><td colspan="1" rowspan="1">Ebola (Ervebo; Merck)</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR169">169</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Toxoid</td><td colspan="1" rowspan="1">Toxins secreted by bacteria; purified and deactivated with formaldehyde</td><td colspan="1" rowspan="1"><p>Safe</p><p>Low rate of side effects</p><p>Stable</p></td><td colspan="1" rowspan="1"><p>Not strongly immunogenic; requires adjuvants</p><p>Requires larger doses and boosters compared with live-attenuated vaccines</p></td><td colspan="1" rowspan="1">Tetanus, diphtheria (TDVAX; MassBiologics)</td><td colspan="1" rowspan="1"> NA</td></tr></tbody></table><table-wrap-foot><p>NA, not applicable.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec4"><title>Challenges and innovations</title><p id="Par7">Materials design can greatly improve vaccination approaches by enabling stabilization and controlled release, and/or by providing delivery devices for self-administration, which is particularly important for vaccines against viruses with a great degree of variability, such as the human immunodeficiency viruses (HIV-1 and HIV-2). HIV-1 shows worldwide variability as well as direct infection and destruction of immune cells. In addition, there is no validated animal model available for HIV-1 research, and the high rate of mutation allows the virus to escape antibody responses to targeted antigens<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. High variability may be addressed by universal vaccines, which are effective against all virus subtypes and are impervious to future mutations by the pathogen. For example, the Gardasil-9 vaccine provides immunity against nine human papillomavirus (HPV) types, which should prevent &gt;90% of HPV infections and subsequent cervical cancer<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>; however, expanding immunity protection to all known HPVs would enable HPV eradication. A universal vaccine against influenza would also greatly decrease infection rates, health-care costs and associated mortality, while improving patient compliance<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Nanotechnology-based approaches, such as HPV-encapsidating microneedles<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> and slow-release implant technologies<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>, could further improve immunization against these difficult pathogens.</p><p id="Par8">Vaccines are also being developed for non-infectious pathophysiological conditions, such as autoimmune diseases and cancers<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. These vaccines are difficult to produce, because the molecular causes and antigens are often specific to the individual patient. Therefore, unlike for infectious disease vaccines, here it may be more advantageous to produce patient-specific vaccines &#8212; a considerable challenge for conventional production methods. Improvements in biotechnology methods, such as whole-exome or RNA sequencing<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>, may allow the isolation of patient-specific antigens for the creation of specialized vaccines.</p><p id="Par9">Nanotechnology-based approaches have also played a key part in the development of COVID-19 mRNA vaccines, although it remains to be seen whether mRNA vaccines will provide long- or short-lasting immunity against SARS-CoV-2. Furthermore, the lack of thermostability of lipid nanoparticle formulations requiring storage and distribution in ultralow-temperature freezers presents a great challenge for vaccine distribution to rural and low-resource regions because these vaccines are temperature-stable only when frozen at &#8211;20 to &#8211;80&#8201;&#176;C. Viral vector vaccines may be better suited for vaccination in remote areas, because they can be stored at higher temperatures of up to 4&#8201;&#176;C. However, early reports suggest that viral vector vaccines do not reduce symptomatic infection as well as mRNA vaccines<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>, although the differing trial protocols and demographics make it difficult to compare the trials equally.</p></sec></sec><sec id="Sec5"><title>Traditional biologics expression</title><p id="Par10">Humulin, the first biologic used in humans<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>, is expressed in <italic toggle="yes">Escherichia coli</italic><sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Advances in DNA technology have further enabled vaccine production in yeast, for example, for the production of subunit vaccines against the hepatitis B virus (HBV)<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. In addition, mammalian cells, insect cells and chicken eggs can be applied as expression systems for vaccine production.</p><p id="Par11">Bacteria are the most widely used expression system, benefiting from low cost, rapid growth and ease of use; in ideal conditions, <italic toggle="yes">E.</italic>&#8201;<italic toggle="yes">coli</italic> can double its biomass within 20&#8201;minutes<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. An estimated 30% of all biopharmaceuticals are currently engineered in bacterial systems, with <italic toggle="yes">E.</italic>&#8201;<italic toggle="yes">coli</italic> being the most widely used strain<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Bacterial systems are also applied to generate DNA plasmids, which are subsequently used to produce the final biologic. The main disadvantage of bacterial systems is the lack of eukaryotic post-translational modifications. Without proper post-translational modification, purified proteins may behave differently in vivo<sup><xref ref-type="bibr" rid="CR26">26</xref></sup> compared with their non-recombinant counterparts, which can lead to diminished or total loss of activity, reduced half-life and decreased stability and/or immunogenicity<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. Moreover, the presence of rare codons in eukaryotic genes can be problematic, because they can cause early termination during bacterial protein production, necessitating the redesign of genes<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>.</p><p id="Par12">To overcome the problems associated with bacterial protein production, mammalian cell lines can be used. From 2016 to 2018, 84% of pharmaceutical proteins were made in mammalian cell lines, predominantly in Chinese hamster ovary (CHO) cells<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. CHO cells achieve high protein yield (up to 10&#8201;g&#8201;l<sup>&#8211;1</sup> for some proteins)<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>, they can grow in suspension<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> and they can withstand changes in external factors, such as temperature and pH<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. However, although post-translational modifications in CHO cells more closely resemble those of human cells, they are not identical and can induce immune or other adverse reactions in patients<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>.</p><p id="Par13">Alternatively, insect cells replicate faster than mammalian cells, enabling faster protein expression, but are more costly than bacteria owing to the requirement of specialized culture media<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. A main disadvantage of insect cells is also the difference in post-translational modifications, as compared with human cells, which can make the biologics immunogenic<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. Furthermore, some insects carry pathogenic viruses (for example, arboviruses) and, thus, insect cell lines must be closely examined before regulatory approval<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. Furthermore, insect cells can produce proteases in response to viral transfection that can digest the protein of interest<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>.</p><p id="Par14">Finally, chicken eggs are widely used for vaccine production, for example, for influenza vaccines<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. Although well established, antigenic drift in chicken eggs can decrease vaccine efficacy, compared with vaccines produced in cell-based systems<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. In addition, vaccine production in chicken eggs can take up to 6&#8201;months, whereas insect cell systems can produce vaccines in 6&#8211;8&#8201;weeks<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. Possible contamination with human pathogens can also be a problem, which can be avoided by molecular farming<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>.</p></sec><sec id="Sec6"><title>Molecular farming</title><p id="Par15">Since the production of HGH in transgenic tobacco<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>, many proof-of-concept and efficacy tests have been performed of plant-made therapeutics and vaccines for humans and animals<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). A tobacco-produced mAb used in the production of a hepatitis B subunit vaccine<sup><xref ref-type="bibr" rid="CR43">43</xref></sup> and a Newcastle disease subunit vaccine for poultry made in cultured tobacco cells were the first plant-made recombinant proteins to receive regulatory approval in 2006 (ref.<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). However, only one human therapeutic (Elelyso, a mitochondrial enzyme deficit therapy for Gaucher disease) produced by molecular farming has thus far been licensed by the US Food and Drug Administration (FDA)<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. In addition, the first phase III human clinical trial for a plant-produced vaccine has just been successfully concluded. This virus like particle (VLP)-based quadrivalent seasonal influenza virus vaccine is currently undergoing final consideration for licensure in Canada<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. The fact that only a few plant-produced therapeutic products have been clinically translated thus far may be more related to industrial and regulatory inertia than to product inadequacy, especially given the plentiful evidence of functional equivalency.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Vaccines and biologics produced by molecular farming</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Pathogen or condition</th><th colspan="1" rowspan="1">Antigenic epitope or biologic</th><th colspan="1" rowspan="1">Plant</th><th colspan="1" rowspan="1">Transformation method</th><th colspan="1" rowspan="1">Company</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td colspan="6" rowspan="1"><bold><italic toggle="yes">Vaccines</italic></bold></td></tr><tr><td colspan="1" rowspan="1">Influenza virus</td><td colspan="1" rowspan="1">Influenza VLP</td><td colspan="1" rowspan="1"><italic toggle="yes">Nicotiana benthamiana</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">Agrobacterium tumefaciens</italic></td><td colspan="1" rowspan="1">Medicago, Inc.</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR170">170</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Hepatitis B virus</td><td colspan="1" rowspan="1">HBsAg</td><td colspan="1" rowspan="1">Tomato</td><td colspan="1" rowspan="1">Agrobacterium</td><td colspan="1" rowspan="1">&#8210;</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR171">171</xref></sup></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Escherichia</italic>&#8201;<italic toggle="yes">coli</italic></td><td colspan="1" rowspan="1">LT-B</td><td colspan="1" rowspan="1">Carrot</td><td colspan="1" rowspan="1">Agrobacterium</td><td colspan="1" rowspan="1">&#8210;</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR172">172</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Rotavirus</td><td colspan="1" rowspan="1">Rotavirus VP7</td><td colspan="1" rowspan="1">Potato</td><td colspan="1" rowspan="1">Agrobacterium</td><td colspan="1" rowspan="1">&#8210;</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR173">173</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Ebola virus</td><td colspan="1" rowspan="1">Ebola glycoprotein (GP1)</td><td colspan="1" rowspan="1"><italic toggle="yes">Nicotiana benthamiana</italic></td><td colspan="1" rowspan="1">Agroinfiltration</td><td colspan="1" rowspan="1">&#8210;</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR174">174</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Foot-and-mouth disease virus</td><td colspan="1" rowspan="1">VP1</td><td colspan="1" rowspan="1">Tobacco</td><td colspan="1" rowspan="1">Biolistic method</td><td colspan="1" rowspan="1">&#8210;</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR175">175</xref></sup></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Plasmodium falciparum</italic></td><td colspan="1" rowspan="1">Pfs25-CP VLP</td><td colspan="1" rowspan="1"><italic toggle="yes">Nicotiana benthamiana</italic></td><td colspan="1" rowspan="1">Agrobacterium</td><td colspan="1" rowspan="1">&#8210;</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR176">176</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Norwalk virus</td><td colspan="1" rowspan="1">Norwalk virus VLP</td><td colspan="1" rowspan="1"><italic toggle="yes">Nicotiana benthamiana</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">Agrobacterium tumefaciens</italic></td><td colspan="1" rowspan="1">&#8210;</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR177">177</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Dengue virus</td><td colspan="1" rowspan="1">Dengue virus type 2 E glycoprotein (EIII)</td><td colspan="1" rowspan="1"><italic toggle="yes">Nicotiana tabacum</italic> cv. MD609</td><td colspan="1" rowspan="1"><italic toggle="yes">Agrobacterium tumefaciens</italic></td><td colspan="1" rowspan="1">&#8210;</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR178">178</xref></sup></td></tr><tr><td colspan="1" rowspan="1">SARS-CoV-2</td><td colspan="1" rowspan="1">VLP</td><td colspan="1" rowspan="1"><italic toggle="yes">Nicotiana benthamiana</italic></td><td colspan="1" rowspan="1">&#8210;</td><td colspan="1" rowspan="1">Medicago, Inc.</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR179">179</xref></sup></td></tr><tr><td colspan="1" rowspan="1">SARS-CoV-2</td><td colspan="1" rowspan="1">RBD of SARS-CoV-2</td><td colspan="1" rowspan="1"><italic toggle="yes">Nicotiana benthamiana</italic></td><td colspan="1" rowspan="1">&#8210;</td><td colspan="1" rowspan="1">Kentucky BioProcessing, Inc.</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR167">167</xref></sup></td></tr><tr><td colspan="1" rowspan="1">SARS-CoV-2</td><td colspan="1" rowspan="1">VLP</td><td colspan="1" rowspan="1">Tobacco</td><td colspan="1" rowspan="1">&#8210;</td><td colspan="1" rowspan="1">iBio, Inc.</td><td colspan="1" rowspan="1">iBio</td></tr><tr><td colspan="1" rowspan="1">SARS-CoV-2</td><td colspan="1" rowspan="1">Spike protein fused with patented LicKM</td><td colspan="1" rowspan="1">Tobacco</td><td colspan="1" rowspan="1">&#8210;</td><td colspan="1" rowspan="1">iBio, Inc.</td><td colspan="1" rowspan="1">iBio</td></tr><tr><td colspan="1" rowspan="1">Avian H5N1 influenza</td><td colspan="1" rowspan="1">Haemagglutinin protein of H5N1</td><td colspan="1" rowspan="1"><italic toggle="yes">Nicotiana benthamiana</italic></td><td colspan="1" rowspan="1">Agrobacterium</td><td colspan="1" rowspan="1">&#8210;</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR180">180</xref></sup></td></tr><tr><td colspan="6" rowspan="1"><bold><italic toggle="yes">Biologics</italic></bold></td></tr><tr><td colspan="1" rowspan="1">Skin rejuvenation</td><td colspan="1" rowspan="1">Basic fibroblast growth factor (bFGF)</td><td colspan="1" rowspan="1"><italic toggle="yes">Nicotiana benthamiana</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">Agrobacterium tumefaciens</italic></td><td colspan="1" rowspan="1">Baiya</td><td colspan="1" rowspan="1">&#8210;</td></tr><tr><td colspan="1" rowspan="1">Skin rejuvenation</td><td colspan="1" rowspan="1">Epidermal growth factor (EGF)</td><td colspan="1" rowspan="1"><italic toggle="yes">Nicotiana benthamiana</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">Agrobacterium tumefaciens</italic></td><td colspan="1" rowspan="1">Baiya</td><td colspan="1" rowspan="1">&#8210;</td></tr><tr><td colspan="1" rowspan="1">Ebola</td><td colspan="1" rowspan="1">ZMapp</td><td colspan="1" rowspan="1"><italic toggle="yes">Nicotiana benthamiana</italic></td><td colspan="1" rowspan="1">magnICON</td><td colspan="1" rowspan="1">Kentucky BioProcessing</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR181">181</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Diabetes</td><td colspan="1" rowspan="1">Insulin</td><td colspan="1" rowspan="1">Safflower</td><td colspan="1" rowspan="1"><italic toggle="yes">Agrobacterium tumefaciens</italic></td><td colspan="1" rowspan="1">SemBioSys</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR182">182</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Neurotoxic agents</td><td colspan="1" rowspan="1">Acetylcholinesterase</td><td colspan="1" rowspan="1">Tobacco</td><td colspan="1" rowspan="1">PEGylated</td><td colspan="1" rowspan="1">Protalix BioTherapeutics</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR183">183</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Inflammatory bowel disease</td><td colspan="1" rowspan="1">Lactoferrin</td><td colspan="1" rowspan="1">Rice (<italic toggle="yes">Oryza sativa</italic> L.)</td><td colspan="1" rowspan="1">ExpressTec</td><td colspan="1" rowspan="1">Ventria</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR184">184</xref></sup></td></tr><tr><td colspan="1" rowspan="1">ETEC</td><td colspan="1" rowspan="1">Lysozyme</td><td colspan="1" rowspan="1">Rice (<italic toggle="yes">Oryza sativa</italic> L.)</td><td colspan="1" rowspan="1">ExpressTec</td><td colspan="1" rowspan="1">Ventria</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR184">184</xref></sup></td></tr><tr><td colspan="1" rowspan="1">SARS-CoV-2</td><td colspan="1" rowspan="1">Neutralizing MAb B38 and H4</td><td colspan="1" rowspan="1"><italic toggle="yes">Nicotiana benthamiana</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">Agrobacterium tumefaciens</italic></td><td colspan="1" rowspan="1">Baiya</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR185">185</xref></sup></td></tr><tr><td colspan="1" rowspan="1">SARS-CoV-2</td><td colspan="1" rowspan="1">Spike glycoprotein S1 antibody CR3022</td><td colspan="1" rowspan="1"><italic toggle="yes">Nicotiana benthamiana</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">Agrobacterium tumefaciens</italic></td><td colspan="1" rowspan="1">Baiya</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR186">186</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Fabry disease</td><td colspan="1" rowspan="1">Pegunigalsidase alfa</td><td colspan="1" rowspan="1">Carrot cells</td><td colspan="1" rowspan="1"><italic toggle="yes">Agrobacterium tumefaciens</italic></td><td colspan="1" rowspan="1">Protalix BioTherapeutics</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR187">187</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Rabies virus</td><td colspan="1" rowspan="1">mAb E559</td><td colspan="1" rowspan="1">Tobacco and maize</td><td colspan="1" rowspan="1">Agrobacterium</td><td colspan="1" rowspan="1">&#8210;</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR188">188</xref></sup></td></tr></tbody></table><table-wrap-foot><p>ETEC, enterotoxigenic <italic toggle="yes">Escherichia coli</italic>; mAb, monoclonal antibody; PEG, polyethylene glycol; RBD, receptor-binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VLP, virus-like particle<sup><xref ref-type="bibr" rid="CR189">189</xref>&#8211;<xref ref-type="bibr" rid="CR195">195</xref></sup>.</p></table-wrap-foot></table-wrap><fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>Timeline of the development of plant molecular farming.</title><p>FDA, US Food and Drug Administration; mAbs, monoclonal antibodies; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; USDA, US Department of Agriculture.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e1506" position="float" orientation="portrait" xlink:href="41578_2021_399_Fig1_HTML.jpg"/></fig></p><p id="Par16">Transgenic plant and plant cell production of proteins laid the foundation of plant molecular farming; however, it was the advent of transient expression technologies that unleashed its true potential, including plant virus-derived vectors, somatic transformation of cells in normal plants (usually by infiltration of <italic toggle="yes">Nicotiana benthamiana</italic> with <italic toggle="yes">Agrobacterium</italic> suspensions), and hybrid methods involving delivery of replicating vectors by <italic toggle="yes">Agrobacterium</italic><sup><xref ref-type="bibr" rid="CR42">42</xref></sup> (Box&#160;<xref rid="Sec7" ref-type="sec">1</xref>). These transient technologies enable protein expression within days of gene cloning, instead of relying on the generation of stable transgenic plants, which can take years. Moreover, yields are usually higher and more consistent, than transgenic plant systems, because these techniques do not depend on genome insertion sites and expression is not downregulated by methylation or other gene modifications, enabling much faster experimentation and optimization of expression. In addition, production scale-up is more efficient than transgenic plants and conventional cell-based technologies. Only a small volume of recombinant <italic toggle="yes">Agrobacterium</italic> suspension has to be grown for the biologic of interest, which can then be combined by agroinfiltration with as many plants &#8212; grown cheaply in nearby facilities &#8212; as required. It is striking that Medicago Inc. received funding from the US Defense Advanced Research Projects Agency (DARPA) Blue Angel initiative to produce ten million doses of current good manufacturing practice (cGMP)-level influenza vaccines 1 month after receiving the sequence of the virus<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. Medicago Inc. has further announced preliminary success in investigating a VLP-based COVID-19 vaccine candidate, which was produced in just over 20 days after receiving the spike protein gene sequence<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. Phase I clinical trial results showed ten times more production of neutralizing antibodies than in convalescent sera<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. This vaccine candidate has recently entered phase II/III clinical trials and is administered along with GlaxoSmithKline&#8217;s AS03 adjuvant<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>.</p><sec id="Sec7"><boxed-text position="float" orientation="portrait"><label>Box 1 Transient expression in plants</label><p id="Par17">Recombinant proteins can be produced in stable transgenic plants<sup><xref ref-type="bibr" rid="CR196">196</xref></sup>, through expression in plant cell cultures<sup><xref ref-type="bibr" rid="CR197">197</xref></sup>, and by transient expression in plants using engineered plant viruses or <italic toggle="yes">Agrobacterium tumefaciens</italic>.</p><p id="Par18">Transient expression in plants can be broken down into four main steps.</p><p id="Par19"><bold><italic toggle="yes">(1) Choosing the plant host.</italic></bold> As with any expression system, it is important to choose a host with desirable characteristics. However, owing to regulatory pressures arising from concerns of possible human and wildlife exposure to modified edible plants, molecular farming is now almost exclusively done in non-edible tobacco plants, such as <italic toggle="yes">Nicotiana benthamiana</italic> and <italic toggle="yes">N.</italic>&#8201;<italic toggle="yes">tabacum</italic>.</p><p id="Par20"><bold><italic toggle="yes">(2) Choosing the vector.</italic></bold> Two different vector types are currently available, that is, <italic toggle="yes">A.</italic>&#8201;<italic toggle="yes">tumefaciens</italic>, which is a plant-tumour-causing bacterium with high capacity for transferring DNA into plants, and plant virus-based vectors, which are often delivered by <italic toggle="yes">A.</italic>&#8201;<italic toggle="yes">tumefaciens</italic>.</p><p id="Par21"><bold><italic toggle="yes">(3) Transfection of plants.</italic></bold> Plants can be transfected by mechanical inoculation, agroinfiltration or vacuum infiltration. In mechanical inoculation, the surface of the plant tissue is inoculated with <italic toggle="yes">A.</italic>&#8201;<italic toggle="yes">tumefaciens</italic> or with linearized plasmids through gentle disturbance of the cell wall. Agroinfiltration can be achieved by infiltrating the vector into cells on the underside of the plant leaves by making a small nick in the epidermis with a syringe. In vacuum infiltration, a vacuum is applied to allow the vectors to penetrate air spaces throughout the entirety of the plant. In addition, agrospray<sup><xref ref-type="bibr" rid="CR198">198</xref></sup> and agrodip<sup><xref ref-type="bibr" rid="CR199">199</xref></sup> approaches have been investigated.</p><p id="Par22"><bold><italic toggle="yes">(4) Purification of the target protein.</italic></bold> Protein purification is achieved by recovery, followed by purification. First, plant tissue and cell walls are broken down to release the protein of interest. The proteins are then separated from the plant homogenates using solid&#8211;liquid separation methods, such as membrane filtration or centrifugation. The solution is then conditioned for the purification process, which usually comprises a series of multistep chromatography methods. The order of chromatography depends on the biologic (for example, monoclonal antibodies are purified on protein A columns), but often ion exchange chromatography is followed by hydrophobic interaction chromatography. Alternatively, affinity chromatography can be applied: a substance that can bind the protein of interest is attached to a solid matrix (for example, antibodies or enzyme substrates) to pull the protein out of solution. Additional tags, which are recognized and bound, can be added to the N- or C-terminus of the protein to aid purification. These tags may, however, interfere with the biological activity of the protein. The tag can subsequently be removed by adding a protease cleavage site between the tag and the protein (for example, a thrombin cleavage site), although this requires an additional round of purification.</p></boxed-text></sec><sec id="Sec8"><title>Algal cell expression</title><p id="Par23">The microalga <italic toggle="yes">Chlamydomonas reinhardtii</italic> is the most commonly used algal system for molecular farming<sup><xref ref-type="bibr" rid="CR49">49</xref></sup> and has been applied to express mAbs (against glycoprotein D of the herpes simplex virus and human fibronectin type III), subunit vaccines (viral protein (VP) 1 of foot-and-mouth disease), allergens (peanut allergens), growth factors (vascular endothelial growth factor), and immunotoxins (chimeric antibody to CD22 and exotoxin A)<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. Although the genomes of the mitochondria, nucleus and chloroplast of <italic toggle="yes">C.</italic>&#8201;<italic toggle="yes">reinhardtii</italic> have been sequenced<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>, expression has been mainly applied in chloroplasts thus far, because the chloroplast genome is small and simple<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>, and biologics can be sequestered in the chloroplast without harming the host cells or being degraded<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. However, similar to bacterial expression, post-translational modifications are lacking in this system. Alternatively, <italic toggle="yes">Lemna</italic> and moss systems have been explored for biologic expression<sup><xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR53">53</xref></sup>.</p></sec><sec id="Sec9"><title>Plants and plant cells</title><p id="Par24">Using plants for vaccine production has the advantage that plants are cheaper than mammalian systems in terms of biomass production, and they have similar protein folding, assembly and glycosylation<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. Therefore, plants can be applied to efficiently produce a range of pharmaceuticals at low cost. It is estimated that the final cost of producing biologics in plants is 68% of that in conventional production systems (site and batch costs are lower in plants, whereas downstream processing costs are identical)<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. Furthermore, post-translational modifications, such as glycosylation, can be manipulated in plants. Thus, plant-produced products have appropriate glycan structures, which can improve half-lives of products and ease downstream processing<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>. For example, Elelyso is considered a &#8216;biobetter&#8217; (biologics that improve upon existing biologics), compared with its CHO-produced counterpart, because the end product contains terminal mannose residues that aid in macrophage receptor binding<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>. In CHO cell production, mannose residues are attached in vitro, adding an extra step and increasing the costs<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>. Influenza virus haemagglutinin proteins made in plants were shown not to induce problematic adverse effects in clinical trials despite non-mammalian glycosylation<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>. In proteins that require human glycosylation, such as the HIV-1 Env gp140 protein, the yield can be substantially increased and the glycosylation pattern of HIV-1 Env gp140 can be altered through coexpression of human chaperonins in <italic toggle="yes">N.</italic>&#8201;<italic toggle="yes">benthamiana</italic> plants, engineered to not produce xylose or fucose transferases<sup><xref ref-type="bibr" rid="CR60">60</xref></sup>.</p><p id="Par25">Plants and plant cells are also inherently safer than bacterial and mammalian systems owing to the low possibility of harmful contamination. In contrast to these systems, plants do not produce endotoxins and cannot be infected by pathogens harmful to humans<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>. Therefore, plants could potentially be used in edible vaccines<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>, although concerns of cross-contamination and accidental vaccination of wildlife have stalled development in this field.</p><p id="Par26">Various vaccine candidates have already been produced by molecular farming, including HIV-1 Env<sup><xref ref-type="bibr" rid="CR60">60</xref></sup>, ten different HPV L1 proteins<sup><xref ref-type="bibr" rid="CR63">63</xref></sup>, West Nile virus envelope protein<sup><xref ref-type="bibr" rid="CR64">64</xref></sup> and dengue virus VLPs<sup><xref ref-type="bibr" rid="CR65">65</xref></sup>. Notably, this list includes three different envelope glycoproteins or their derivatives. In addition, a recombinant double-stranded DNA (dsDNA) molecule has been encapsidated in HPV-16 pseudovirions, which were made in plants<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>, proving that DNA vaccines and their delivery systems can be succesfully produced in plants. Similarly, mRNA vaccines can be produced in plants; for example, recombinant mRNA molecules can be expressed in plants from DNA vectors and specifically encapsidated by adding an assembly signal in tobacco mosaic virus (TMV) coat proteins. Synthetic mRNAs made in vitro can also be encapsidated with purified TMV coat proteins, which was first demonstrated in 1956 with TMV RNA<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. Encapsulation of target and self-replicating mRNA can be achieved in plants through co-expression of the desired mRNA and the TMV coat proteins<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>, making this an attractive and scalable approach towards plant-produced mRNA vaccines.</p><p id="Par27">The limited commercialization of plant cell culture-based expression systems may be related to the lower protein yield (usually 0.01&#8211;10&#8201;mg&#8201;l<sup>&#8211;1</sup>, although up to 247&#8201;mg&#8201;l<sup>&#8211;</sup><sup>1</sup> have been reported)<sup><xref ref-type="bibr" rid="CR68">68</xref></sup>, compared with bacterial and mammalian cell culture, which can achieve up to 10&#8201;g&#8201;l<sup>&#8211;1</sup> (ref.<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>). Additionally, controlling the expression levels of certain proteins remains difficult, especially in transgenic plants. Expression can vary between different generations of plants, is highly dependent on the plant type, and can even fluctuate within the same plant&#8217;s tissues and organs<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. Plants may also suffer from variability of environmental conditions, such as droughts and extreme heat &#8212; although this is less problematic in growth houses.</p><sec id="Sec11"><title>Cookie technique</title><p id="Par28">The cookie technique, that is, the transient transformation of plant cells to produce high-value proteins, may revolutionize the small-scale production of recombinant proteins and other biologics in cultured plant cells<sup><xref ref-type="bibr" rid="CR69">69</xref></sup>. Here, cell packs or &#8216;cookies&#8217; are made on porous supports by filtration of suspended cells, followed by incubation with <italic toggle="yes">Agrobacterium</italic> suspensions without resuspension. The bacteria are then washed out with growth medium, leaving behind a mass with many air spaces. The treatment results in transformation rates of up to 100%, compared with around 1% from co-incubation of cells with <italic toggle="yes">Agrobacterium</italic> in suspension<sup><xref ref-type="bibr" rid="CR70">70</xref></sup>. Cell packs can be incubated for days in situ and can produce up to 47&#8201;mg&#8201;kg<sup>&#8211;1</sup> of recombinant protein. The technique is scalable from microlitre and millilitre volumes up to large-volume preparative columns used for filtration or chromatography, and thus can be used for high-throughput and low-volume screening and for subsequent production of trial batches of proteins.</p></sec></sec><sec id="Sec10"><title>Clinical applications of molecular farming</title><sec id="Sec12"><title>Patient-specific antigens</title><p id="Par29">Although molecular farming may not displace fermentation and large-volume cell culture for the production of blockbuster vaccines and therapeutics, it may be advantageous in certain applications; for example, for patient-specific or individualized production of antigens for therapeutic vaccines, which are required for certain diseases, such as non-Hodgkin lymphoma<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>. mAbs can be produced with relative ease in plants and, thus, non-Hodgkin lymphoma was an early target for molecular farming<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>. Here, the mAbs are produced by introducing recombinant TMV (magnICON) vectors into <italic toggle="yes">N.</italic>&#8201;<italic toggle="yes">benthamiana</italic> plants using <italic toggle="yes">Agrobacterium</italic><sup><xref ref-type="bibr" rid="CR73">73</xref></sup>. Grams of purified protein, enough for a lifetime supply for a patient, were produced at a cost of only about US$15,000 (2015); for comparison, production by conventional expression systems is estimated to cost around ten times more.</p></sec><sec id="Sec13"><title>Niche and orphan diseases</title><p id="Par30">Molecular farming also has potential for the production of niche or orphan vaccines as well as therapies, for which the market is perceived as too small to invest in a potential vaccine (for example, Lassa fever in West Africa), and/or the target market cannot afford the costs (for example, Rift Valley fever in East Africa). Importantly, such niche or orphan diseases have a role in the One Health Initiative, which aims to produce reagents for a disease that can infect wildlife, livestock or humans and to repurpose these into vaccines for animals or humans<sup><xref ref-type="bibr" rid="CR74">74</xref></sup>. For example, the nucleoproteins of both Crimean&#8211;Congo haemorrhagic fever<sup><xref ref-type="bibr" rid="CR75">75</xref></sup> and Rift Valley fever<sup><xref ref-type="bibr" rid="CR76">76</xref></sup> bunyaviruses have been produced in plants with high yield and used in validated serological assays. In addition, SARS-CoV-2 spike glycoproteins have been made in plants in various forms for laboratories and detection kit manufacturers<sup><xref ref-type="bibr" rid="CR77">77</xref></sup>.</p></sec><sec id="Sec14"><title>Virus nanoparticles and virus-like particles</title><p id="Par31">Plant virus-derived VNPs are best produced in their natural hosts, that is, plants, by infection or recombinant expression, yielding milligrams of VNPs or VLPs per gram of leaf tissue<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. VLPs are the non-infectious version of VNPs and do not contain the viral genome. Plant VNPs are proteinaceous nanomaterials that self-assemble into precise geometries at the nanometre scale. Many of their coat proteins have been mapped to near-atomic resolution, allowing functionalization with spatial control; molecular payloads can be incorporated into the interior cavity, integrated at interfaces, or displayed at the surface using an array of chemical biology approaches<sup><xref ref-type="bibr" rid="CR78">78</xref></sup> (Fig.&#160;<xref rid="Fig2" ref-type="fig">2a</xref>&#8211;<xref rid="Fig2" ref-type="fig">c</xref>). Thus, VNPs can be used as nanocarriers with a variety of payloads, including small-molecule drugs and prodrugs, nucleic acids, therapeutic proteins, contrast agents and photosensitizers for drug delivery<sup><xref ref-type="bibr" rid="CR79">79</xref></sup>, vaccines<sup><xref ref-type="bibr" rid="CR80">80</xref></sup>, diagnosis<sup><xref ref-type="bibr" rid="CR81">81</xref></sup>, theranostics<sup><xref ref-type="bibr" rid="CR82">82</xref></sup>, catalysis<sup><xref ref-type="bibr" rid="CR83">83</xref></sup>, live imaging<sup><xref ref-type="bibr" rid="CR84">84</xref></sup> and agricultural applications<sup><xref ref-type="bibr" rid="CR85">85</xref></sup>. Plant-made VNPs confer additional safety benefits compared with their mammalian viral vector counterparts because plant viruses are non-infectious to mammals<sup><xref ref-type="bibr" rid="CR86">86</xref></sup>. Therefore, this technology is ideal for human vaccines and immunotherapies.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>Structure and engineering design space of plant virus nanotechnologies and virus-like particle vaccines.</title><p><bold>a</bold> | Display of epitopes or peptides on cowpea mosaic virus (CPMV) through genetic fusion or bioconjugation. <bold>b</bold> | Encapsidation of molecular payloads within the cowpea chlorotic mosaic virus (CCMV) through dis-assembly and re-assembly of coat proteins following changes in the solvent conditions. <bold>c</bold> | Delivery of molecular payloads with tobacco mosaic virus (TMV) using internal glutamate (Glu) or external tyrosine (Tyr) residues. Therapeutic payloads can be loaded into the interior of the TMV or conjugated to the exterior surface of TMV. <bold>d</bold> | Epitope delivery using plant viral nanoparticles (VNPs). Vaccination with VNPs leads to intracellular processing of the antigen or genomic material encoding the antigen. The antigen is then displayed on the cell surface, leading to the activation of CD4<sup>+</sup> and CD8<sup>+</sup> T cells. CD4<sup>+</sup> T cells go on to activate memory B cells, leading to immune memory against future infections. APC, antigen-presenting cell; BCR, B cell receptor; MHC, major histocompatibility complex; VLP, virus-like particle. The plant VNPs were drawn using UCSF Chimera (CPMV PDB ID: 1NY7; CCMV PDB ID: 1CWP; TMV PDB ID: 2TMV), and parts of Fig.&#160;<xref rid="Fig3" ref-type="fig">3d</xref> were made using <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://smart.servier.com/">https://smart.servier.com/</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e1928" position="float" orientation="portrait" xlink:href="41578_2021_399_Fig2_HTML.jpg"/></fig></p><p id="Par32">Although non-infectious to mammals, the repetitive, multivalent coat protein assemblies are pathogen-associated molecular patterns (PAMPs) that act as danger signals. VNPs administered via various routes (including subcutaneously and intramascular) drain efficiently to lymph nodes and activate immune cells upon recognition by pattern recognition receptors. VNP-based vaccines also facilitate antigen cross-presentation, which is crucial for major histocompatibility complex class I (MHC-I) presentation of extracellular antigens to trigger a robust cytotoxic T cell response. For example, plant VNPs, including papaya mosaic virus, TMV and potato virus X, can generate robust cellular responses against fused epitopes<sup><xref ref-type="bibr" rid="CR87">87</xref></sup>. The potency of the immunostimulatory properties of VNPs has been demonstrated in an in situ cowpea mosaic virus (CPMV) vaccine, showing remarkable efficacy in animal models of melanoma, glioma, breast, colon and ovarian cancer<sup><xref ref-type="bibr" rid="CR88">88</xref>&#8211;<xref ref-type="bibr" rid="CR92">92</xref></sup>. Here, the VNPs are administered directly into the tumour to stimulate innate immune cells within the tumour microenvironment, priming tumour cell killing and antigen processing, which results in systemic antitumour immunity. In contrast to oncolytic viral tumour therapy, pre-existing immunity does not decrease the effectiveness of the immune response induced by the VNPs<sup><xref ref-type="bibr" rid="CR89">89</xref></sup>. Instead, antibody recognition increases opsonization of CPMV, thereby improving the recognition of the virus by innate immune cells, which are its natural targets. The CPMV cancer immunotherapy has also shown efficacy in companion animals with spontaneous tumours<sup><xref ref-type="bibr" rid="CR93">93</xref></sup>. Therefore, VNPs are excellent epitope delivery platforms for antigens (Fig.&#160;<xref rid="Fig2" ref-type="fig">2d</xref>) and adjuvants for vaccine and immunotherapy applications<sup><xref ref-type="bibr" rid="CR94">94</xref></sup>. The current preclinical development pipeline for VNP-based vaccines includes infectious, cardiovascular and autoimmune diseases as well as substance abuse<sup><xref ref-type="bibr" rid="CR95">95</xref></sup>. Plant VNP vaccine platform technologies also hold promise for pandemic or epidemic vaccines<sup><xref ref-type="bibr" rid="CR96">96</xref></sup> &#8212; owing to their high thermal stability they would not be subject to cold chain distribution and/or could be produced in the region for the region through molecular farming.</p></sec></sec></sec><sec id="Sec15"><title>Distribution challenges of vaccines</title><p id="Par33">The successful vaccination of entire populations in low-resource areas is an arduous task, which will require addressing distribution challenges in relation to cold chain failures and the lack of trained health-care providers with vaccine experience<sup><xref ref-type="bibr" rid="CR97">97</xref></sup>.</p><sec id="Sec16"><title>The cold chain</title><p id="Par34">The majority of traditional (live and inactivated) vaccines approved for use are advised to be distributed through the cold chain at 2&#8211;8&#8201;&#176;C for optimal activity. The cold chain is a temperature-controlled supply chain of the people, equipment and protocols used in the transportation, storage and handling of vaccines from manufacturer to patient (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). When disrupted, vaccine denaturation can lead to less effective vaccines with greater side effects. The &#8216;last mile&#8217; vaccine distribution, describing the allocation of vaccines from national distribution centres to regional facilities and patients, is especially challenging, as evidenced in the SARS-CoV-2 vaccine rollout. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/immunization/call-to-action_ipac-iscl.pdf">The World Health Organization (WHO)</ext-link> reported that in 2011, 2.8 million vaccine doses were lost owing to cold chain disruptions in five countries surveyed. Therefore, in 2012, the WHO expressed a preference for vaccines that are heat- and freeze-stable for extended periods above 8&#8201;&#176;C, as a part of the controlled temperature chain<sup><xref ref-type="bibr" rid="CR98">98</xref></sup>.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><title>The cold chain of vaccines.</title><p>The cold chain is a temperature-controlled supply chain of the people, equipment and protocols used in the transportation, storage and handling of vaccines from the manufacturer to the patient.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e2002" position="float" orientation="portrait" xlink:href="41578_2021_399_Fig3_HTML.jpg"/></fig></p><p id="Par35">Cold chain disruptions can occur from a variety of sources. Vaccines can be exposed to extended periods of heating owing to electricity and power outages, equipment failure, limited ice supplies, and transportation and delivery delays<sup><xref ref-type="bibr" rid="CR99">99</xref></sup>. Vaccine function can also be compromised by vaccine freezing owing to ice build-up in refrigerators or improper ice conditioning<sup><xref ref-type="bibr" rid="CR98">98</xref></sup>.</p></sec><sec id="Sec17"><title>Immunization challenges</title><p id="Par36">Overcoming immunization challenges requires collaboration between multiple parties involved in the vaccine supply chain. First, a better understanding of the impact of heat or freeze exposure on vaccine stability is needed. The WHO further demands that all vaccines purchased by the United Nations Children&#8217;s Fund must have vaccine vial monitors<sup><xref ref-type="bibr" rid="CR100">100</xref></sup> that measure cumulative heat exposure and signal whether the vaccine should be discarded in case of cold chain disruptions. Vaccine vial monitors are cheap and indispensable; however, they can fail; for example, an oral polio vaccine with a 48-hour controlled temperature chain (indicated by the manufacturer) maintained viable potency for up to 86.9 hours above 8&#8201;&#176;C, even though the vaccine vial monitor indicated it had reached its end point<sup><xref ref-type="bibr" rid="CR101">101</xref></sup>. In addition, it is important that health-care professionals are trained to read and interpret vaccine vial monitor data and in handling procedures, such as preventing sunlight exposure, which can lead to false positives and premature vaccine discards<sup><xref ref-type="bibr" rid="CR102">102</xref></sup>. Similarly, freeze indicators and shake-tests for freeze-induced protein aggregation can measure potency, in cases when freezing temperatures are a concern<sup><xref ref-type="bibr" rid="CR98">98</xref></sup>.</p><p id="Par37">Thermostable liquid and dry vaccine formulations can further address cold chain-related challenges. Liquid vaccines can benefit from high-throughput optimization of formulation properties, such as buffer type, pH and ionic strength, to improve stability. Dry vaccines can be more thermostable but must be reconstituted before use. Reconstitution is limited by large product volumes, logistical concerns, and potential sources of error and contaminants. Dry vaccines need simple-to-use reconstitution systems or strategies to bypass the need for reconstitution, for example, by applying aerosols, dry powder jet injection, microneedle patches or biodegradable implants<sup><xref ref-type="bibr" rid="CR103">103</xref></sup>. Moreover, the ability to withstand temporary storage or transport without refrigeration or ice would help mitigate cold chain disruptions, particularly in areas where health workers travel by foot<sup><xref ref-type="bibr" rid="CR104">104</xref></sup> or where there is a lack of cold boxes<sup><xref ref-type="bibr" rid="CR102">102</xref></sup>.</p></sec><sec id="Sec18"><title>Health personnel</title><p id="Par38">Health-care workers connect every step of the vaccine supply chain and, thus, require adequate training for each vaccine, including reconstitution methods, handling of the cold chain and controlled-temperature chain, and reading of vaccine vial monitors. Negligent handling may result in wasted vaccines or the delivery of ineffective vaccines<sup><xref ref-type="bibr" rid="CR103">103</xref></sup>. Therefore, easy-to-use vaccines that require less training may reduce human error, for example, single-use or self-administered systems. UniJect, which is a pre-filled single-use system<sup><xref ref-type="bibr" rid="CR105">105</xref></sup>, is easy to use, activated by simply pushing the needle through a membrane and into the drug reservoir, and its valve ensures that the vaccine can only be used once by preventing the needle from retracting. The UniJect system has also been reported to be less painful and anxiety-inducing for patients<sup><xref ref-type="bibr" rid="CR105">105</xref></sup>.</p></sec><sec id="Sec19"><title>Cost per dose</title><p id="Par39">The definition of successful vaccine implementation could further be redefined from cost per dose to cost per dose delivered, to reflect the true cost of introducing a new vaccine<sup><xref ref-type="bibr" rid="CR104">104</xref></sup>. A higher cost per dose would probably be accepted for a more stable vaccine, because of reduced wastage, lower storage and handling costs, better efficacy and protection, and easier management, as compared with less-stable vaccines, making it more cost-effective overall. For example, single-use systems, such as UniJect, add $US0.15&#8211;0.30 to the cost per dose, compared with traditional single-use syringes; however, the 20% wastage rate for multi-dose vials and the fact that UniJect can be administered at home lead to a decrease in cost per dose delivered, from $US7.19 to $US6.57 in the case of tetanus<sup><xref ref-type="bibr" rid="CR106">106</xref></sup>. Therefore, dose-sparing technologies in vaccine manufacturing, deployment and administration can have a substantial impact on immunization success and costs.</p></sec><sec id="Sec20"><title>Plant molecular farming to overcome vaccination challenges</title><p id="Par40">Plants can be used to produce vaccines at small scale and low cost in regions where vaccines are most needed, particularly in areas where it may be difficult to set up cGMP-level bacterial and mammalian cell culture systems. In addition, contaminants from plant molecular farming are not as harmful as endotoxins produced in bacterial expression<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>. Moving vaccine manufacturing on-site would also reduce cold chain requirements, because long-distance shipping would not be needed; this has been especially highlighted during the SARS-CoV-2 vaccine rollout. In 67 low-income countries, an estimated 90% of the population may not gain access to any SARS-CoV-2 vaccine in 2021 (ref.<sup><xref ref-type="bibr" rid="CR107">107</xref></sup>). Therefore, plant molecular farming could reduce vaccine inequity and immunization costs<sup><xref ref-type="bibr" rid="CR108">108</xref></sup>. Furthermore, production of vaccines by plant molecular farming does not require extensive space; for example, it was calculated that Italy could reach a 60% vaccination rate with 12,500 square metres of greenhouses<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. Moreover, molecular farming is easily scalable, compared with fermentation systems, which must be adapted and optimized for scale-up, and which require costly bioreactors. By contrast, each plant is a bioreactor, and scale-up is simply achieved by growing more plants.</p><p id="Par41">Plant molecular farming is particularly useful for producing plant viruses as nanocarriers for vaccines. Plant VNPs are very stable and can withstand temperatures outside cold chain requirements; for example, CPMV withstands temperatures of 37&#8201;&#176;C for 46&#8201;days<sup><xref ref-type="bibr" rid="CR109">109</xref></sup> and 60&#8201;&#176;C for up to 1&#8201;hour<sup><xref ref-type="bibr" rid="CR110">110</xref></sup>. Thermostability is especially important in areas in which resources for adequate cold chain distribution of vaccines may be limited. Furthermore, plant viruses, owing to their intrinsic stability, can withstand the processing and manufacturing steps of vaccine packaging into new administration technologies, such as microneedles<sup><xref ref-type="bibr" rid="CR96">96</xref></sup>. VNPs do not only act as carriers, but also as adjuvants, reducing the number of vaccine components. Moreover, the simplicity of VNP-based vaccines can improve health-care worker compliance and reduce the need for training in vaccine administration.</p></sec></sec><sec id="Sec21"><title>Vaccine administration technologies</title><p id="Par42">Administration of vaccines with hypodermic needles, which is currently the most frequently used administration technology, has several drawbacks. For example, blood-borne pathogens can easily be spread by needle reuse or mishandling<sup><xref ref-type="bibr" rid="CR111">111</xref></sup>. Moreover, patients may be apprehensive about needles<sup><xref ref-type="bibr" rid="CR112">112</xref></sup>. Vaccines delivered by hypodermic needles also rely on liquid formulations for injections, which require a cold chain<sup><xref ref-type="bibr" rid="CR113">113</xref></sup>.</p><p id="Par43">To overcome these obstacles, vaccines can be encapsulated in polymeric materials. Proteins in the solid state embedded within a polymer matrix further improve the thermal stability of the vaccine, thereby decreasing strict adherence to the cold chain<sup><xref ref-type="bibr" rid="CR114">114</xref></sup>. Polymeric materials could be used in new vaccine delivery platforms that could supplant hypodermic needles, improving patient compliance and reducing the unintended spread of blood-borne pathogens. Next-generation polymeric delivery platforms that are safe, effective and self-administered could thus greatly strengthen concerted vaccination efforts.</p><sec id="Sec22"><title>Polymeric materials</title><p id="Par44">Considerable research has been devoted to the development of biocompatible and biodegradable polymeric materials for vaccines<sup><xref ref-type="bibr" rid="CR115">115</xref></sup> (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). These materials can be of synthetic or natural origin, and processing and manufacturing requirements can differ for each polymer, which may restrict the use of biological components. For example, inactivated or live attenuated vaccines can denature at high temperatures, which restricts the processing conditions (some processes require temperatures above 70&#8201;&#176;C) required to encapsulate these vaccines in polymeric materials<sup><xref ref-type="bibr" rid="CR113">113</xref></sup>. By contrast, VLPs and VNPs are chemo- and thermostable, enabling a broader array of device manufacturing conditions<sup><xref ref-type="bibr" rid="CR116">116</xref></sup>. Fabricated by plant molecular farming, VLPs and VNPs can be produced at large scales for material integration at lower cost, as compared with conventional inactivated or live attenuated vaccines<sup><xref ref-type="bibr" rid="CR108">108</xref></sup>.<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Biocompatible polymers for vaccine delivery</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Polymer</th><th colspan="1" rowspan="1">Structure</th><th colspan="1" rowspan="1">Biodegradation</th><th colspan="1" rowspan="1">Properties</th><th colspan="1" rowspan="1">Vaccine delivery method</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td colspan="6" rowspan="1"><bold><italic toggle="yes">Polyesters</italic></bold></td></tr><tr><td colspan="1" rowspan="1">Poly(&#949;-caprolactone) (PCL)</td><td colspan="1" rowspan="1"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e2208" xlink:href="41578_2021_399_Taba_HTML.gif"/></td><td colspan="1" rowspan="1">2&#8211;4 years</td><td colspan="1" rowspan="1"><p>Does not generate acidic environment upon degradation</p><p>Adjuvant properties</p><p>Slow degradation only suitable for long-term delivery applications</p></td><td colspan="1" rowspan="1">NP, MP</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR189">189</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Poly(lactic acid) (PLA)</td><td colspan="1" rowspan="1"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e2234" xlink:href="41578_2021_399_Tabb_HTML.gif"/></td><td colspan="1" rowspan="1">3&#8211;8 months</td><td colspan="1" rowspan="1"><p>Tunable degradation depending on chirality of monomers</p><p>Adjuvant properties</p></td><td colspan="1" rowspan="1">NP, MP</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR190">190</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Poly(lactic-co-glycolic acid) (PLGA)</td><td colspan="1" rowspan="1"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e2258" xlink:href="41578_2021_399_Tabc_HTML.gif"/></td><td colspan="1" rowspan="1">1&#8211;6 months</td><td colspan="1" rowspan="1"><p>Tunable degradation depending on monomer ratios in copolymer</p><p>Degradation produces acidic environment</p><p>Protein encapsulation can cause denaturation</p></td><td colspan="1" rowspan="1">NP, MP, MN</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR118">118</xref></sup></td></tr><tr><td colspan="6" rowspan="1"><bold><italic toggle="yes">Polyanhydrides</italic></bold></td></tr><tr><td colspan="1" rowspan="1">Poly[1,6-bis(p-carboxyphenoxy)hexane-co-sebacic acid] (PCPH-SA)</td><td colspan="1" rowspan="1"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e2289" xlink:href="41578_2021_399_Tabd_HTML.gif"/></td><td colspan="1" rowspan="1">2&#8211;10 weeks</td><td colspan="1" rowspan="1"><p>Tunable degradation and material properties owing to synthetic flexibility</p><p>Adjuvant properties</p><p>Freezing and anhydrous conditions required for storage</p></td><td colspan="1" rowspan="1">NP, MP</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR127">127</xref></sup></td></tr><tr><td colspan="6" rowspan="1"><bold><italic toggle="yes">Polyphosphazene</italic></bold></td></tr><tr><td colspan="1" rowspan="1">Poly[di(carboxylatophenoxy)phosphazene] (PCPP)</td><td colspan="1" rowspan="1"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e2320" xlink:href="41578_2021_399_Tabe_HTML.gif"/></td><td colspan="1" rowspan="1">1&#8211;24 months</td><td colspan="1" rowspan="1"><p>Tunable degradation and material properties owing to synthetic flexibility</p><p>Buffering capacity of degradation products</p><p>Adjuvant properties</p></td><td colspan="1" rowspan="1">NP, MP, coated MN</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR191">191</xref></sup></td></tr><tr><td colspan="6" rowspan="1"><bold><italic toggle="yes">Polysaccharides</italic></bold></td></tr><tr><td colspan="1" rowspan="1">Chitosan</td><td colspan="1" rowspan="1"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e2351" xlink:href="41578_2021_399_Tabf_HTML.gif"/></td><td colspan="1" rowspan="1">14&#8211;60 days</td><td colspan="1" rowspan="1"><p>Encapsulation of antigens in aqueous media</p><p>Mucoadhesive properties</p><p>Adjuvant properties</p><p>High variability in quality from commercial sources can affect degradation and immunogenicity</p></td><td colspan="1" rowspan="1">NP, MP, MN, coated MN</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR144">144</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Hyaluronic acid (HA)</td><td colspan="1" rowspan="1"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e2379" xlink:href="41578_2021_399_Tabg_HTML.gif"/></td><td colspan="1" rowspan="1">&#8201;&lt;24&#8201;hours</td><td colspan="1" rowspan="1"><p>Rapid dissolution in the skin</p><p>Adjuvant properties</p><p>Not suitable for long-term delivery applications</p></td><td colspan="1" rowspan="1">MN</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR192">192</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Dextran</td><td colspan="1" rowspan="1"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e2406" xlink:href="41578_2021_399_Tabh_HTML.gif"/></td><td colspan="1" rowspan="1">1&#8211;42&#8201;hours</td><td colspan="1" rowspan="1"><p>Rapid dissolution in the skin</p><p>Microparticle formulations require chemical modification of dextran</p></td><td colspan="1" rowspan="1">MP, MN</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR193">193</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Alginate</td><td colspan="1" rowspan="1"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e2430" xlink:href="41578_2021_399_Tabi_HTML.gif"/></td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1"><p>Encapsulation of antigens in aqueous media</p><p>Mucoadhesive properties</p><p>Adjuvant properties</p><p>Stable at low pH, facilitating oral immunization</p><p>High variability in quality from commercial sources can affect degradation and immunogenicity</p><p>Limited in vivo degradation unless chemically modified</p></td><td colspan="1" rowspan="1">MP, MN</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR194">194</xref></sup></td></tr><tr><td colspan="6" rowspan="1"><bold><italic toggle="yes">Non-biodegradable polymers</italic></bold></td></tr><tr><td colspan="1" rowspan="1">Polyvinylalcohol (PVA) or polyvinylpyrrolidone (PVP)</td><td colspan="1" rowspan="1"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e2467" xlink:href="41578_2021_399_Tabj_HTML.gif"/></td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1"><p>Rapid dissolution in the skin</p><p>Non-biodegradable</p></td><td colspan="1" rowspan="1">MN</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR195">195</xref></sup></td></tr></tbody></table><table-wrap-foot><p>MN, microneedle; MP, microparticle; NA, not applicable; NP, nanoparticle.</p></table-wrap-foot></table-wrap></p><p id="Par45">Polymeric materials, developed for next-generation vaccine administration, generally act as delivery vehicles, allowing the controlled release of antigen and adjuvant over weeks to years, depending on the type of material. The antigen release rate can be controlled by tuning the material properties. The presence of degradable bonds in the polymer&#8217;s backbone and its hydrophilicity, molecular weight and crystallinity influence the degradation rate of both synthetic and natural polymers. For example, to enable instantaneous burst release, antigens can be encapsulated in rapidly dissolving water-soluble polymers, such as polyvinylpyrrolidone (PVP), which can be processed into microneedles for intradermal vaccine delivery<sup><xref ref-type="bibr" rid="CR117">117</xref></sup>. A slow and sustained release can be achieved by choosing slowly degrading polymers, such as poly(lactic-co-glycolic acid) (PLGA)<sup><xref ref-type="bibr" rid="CR118">118</xref></sup>. Increasing the window of antigen delivery can further improve the efficacy of vaccines<sup><xref ref-type="bibr" rid="CR119">119</xref>,<xref ref-type="bibr" rid="CR120">120</xref></sup>. By combining burst and slow-release strategies, single-dose regimens can be designed that mimic the multi-dose prime&#8211;boost regimen of conventional vaccines<sup><xref ref-type="bibr" rid="CR121">121</xref></sup>; for example, a vaccine could be encapsulated in both a burst-release polymer and a slow-release polymer, which can then be simultaneously administered.</p><p id="Par46">Delivery of adjuvants is key for vaccines. Some subunit vaccines, such as VLPs or recombinant VLPs and VNPs, which deliver subunit antigens, may not require additional adjuvants because the VLP or VNP itself acts as the adjuvant through recognition and activation of pattern recognition receptors<sup><xref ref-type="bibr" rid="CR122">122</xref></sup>. However, for moderately or poorly immunogenic antigens, adjuvants need to be added to the formulation. The most frequently used adjuvants are aluminium-based salts (alum)<sup><xref ref-type="bibr" rid="CR113">113</xref></sup>, which serve both as a delivery vehicle by adsorbing antigen to the surface and as an immunostimulator by inducing pro-inflammatory signalling cascades<sup><xref ref-type="bibr" rid="CR123">123</xref></sup>. Similarly, polymers such as alginate, hyaluronic acid and PLGA can act as both delivery vehicle and adjuvant owing to their natural inflammatory properties<sup><xref ref-type="bibr" rid="CR124">124</xref></sup>. Further activation of innate immunity can be achieved through co-delivery of Toll-like receptor (TLR) ligands, such as CpG-oligodeoxynucleotide or monophosphoryl lipid A. Here, materials design is crucial, because a growing body of data suggests that co-delivery of adjuvant and antigen to the same antigen-presenting cell is important to enhance vaccine efficacy and to increase safety by lowering the likelihood of an uncontrolled and unspecific systemic immune response<sup><xref ref-type="bibr" rid="CR125">125</xref></sup>.</p></sec><sec id="Sec23"><title>Vaccine delivery devices and production</title><p id="Par47">As an alternative to subcutaneous injection with hypodermic needles, other routes of administration have been explored, using different device designs and fabrication, which have a considerable effect on immunostimulation. Here, we discuss two delivery constructs for vaccine self-administration: nano- and microparticle formulations, and microneedle patches. Using these devices, vaccines can be self-administered by intradermal, intranasal or oral administration (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><title>Market analysis and development pipeline of vaccine delivery technologies.</title><p><bold>a</bold> | Number of research publications for microneedle, microparticle and nanoparticle vaccine delivery technologies. The terms &#8216;microneedle&#8217;, &#8216;microparticle&#8217; and &#8216;nanoparticle&#8217; were searched on PubMed, and the total number of publications for each search term were graphed with respect to publication date. <bold>b</bold> | Percentage distribution of biocompatible synthetic and natural polymers frequently used in research publications for vaccine delivery. The number of research publications on PubMed mentioning the respective polymers were counted for each polymer listed in the figure and totalled. The respective percentage of each polymer was then calculated from the total and graphed. <bold>c</bold> | Number of patent applications for microneedle, microparticle and nanoparticle vaccine delivery technologies. The terms &#8216;microneedle&#8217;, &#8216;microparticle&#8217; and &#8216;nanoparticle&#8217; were searched on <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.uspto.gov">www.uspto.gov</ext-link>, and the total number of publications for each search term was graphed with respect to publication date. <bold>d</bold> | Routes of administration for vaccine delivery proposed by patent applications. The number of patents mentioning the respective route of administration as well as the term &#8220;vaccine&#8221; were counted on <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.uspto.gov">www.uspto.gov</ext-link> and totalled. The respective percentage of each route of administration was then calculated from the total and graphed.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e2569" position="float" orientation="portrait" xlink:href="41578_2021_399_Fig4_HTML.jpg"/></fig></p><sec id="Sec24"><title>Nano- and microparticles</title><p id="Par48">Vaccines can be encapsulated in polymeric nano- and microparticles. For example, polyester-based microparticles, such as PLGA microparticles, can be fabricated starting with an initial water-in-oil dispersion of polymer and antigen, followed by an additional emulsion and solvent removal step, polymer phase separation or spray drying<sup><xref ref-type="bibr" rid="CR126">126</xref></sup>. By contrast, polyanhydrides require completely anhydrous conditions (solid&#8211;oil&#8211;oil dispersions) to prevent premature polymer hydrolysis<sup><xref ref-type="bibr" rid="CR127">127</xref></sup>. Antigens can also be encapsulated in ionic polymers, such as polyphosphazenes and polysaccharides, by crosslinking of the polymers through the addition of oppositely charged multivalent ions in aqueous and ambient conditions. However, these fabrication techniques have several drawbacks, which can limit their use for certain biologics. For example, water-in-oil dispersion has low encapsulation efficiencies, which may limit its use for expensive and difficult-to-produce biologics<sup><xref ref-type="bibr" rid="CR128">128</xref></sup>. Importantly, the fabrication process can affect antigen stability<sup><xref ref-type="bibr" rid="CR129">129</xref></sup>; for example, antigens can degrade or unfold owing to interactions at the aqueous&#8211;organic interface or to high shear forces during emulsification<sup><xref ref-type="bibr" rid="CR130">130</xref></sup>.</p><p id="Par49">Nano- and microparticles are often used in self-administered intranasal vaccines. Here, antigens are encapsulated within nano- or microparticles, usually made of poly(lactic acid) or PLGA, and administered as a spray or aerosol, ideally targeting immune cells that reside in the nasal-associated lymphoid tissue of the upper respiratory tract<sup><xref ref-type="bibr" rid="CR131">131</xref></sup>. However, following intranasal administration, the mucociliary clearance mechanism may clear the deposited vaccine particles, with a half-life of around 20&#8201;minutes<sup><xref ref-type="bibr" rid="CR132">132</xref></sup>. To prevent rapid clearance, the vaccines can be formulated with mucoadhesive polymers, such as chitosan, which can translocate across the nasal mucosal barrier and prolong the residence time to hours or days to improve the immune response<sup><xref ref-type="bibr" rid="CR133">133</xref></sup>.</p></sec><sec id="Sec25"><title>Microneedles</title><p id="Par50">Microneedles are microscale projections, usually 50 to 900&#8201;&#956;m in height, which can pierce the upper layers of the skin and facilitate transdermal delivery of vaccines<sup><xref ref-type="bibr" rid="CR134">134</xref></sup>. Microneedles do not puncture deep enough to activate the nociceptors within the skin and are therefore considered painless. Microneedles can achieve greater immunological responses, compared with traditional routes of administration, such as intramuscular or subcutaneous injection, owing to the abundant immune cell population in the upper layers of the skin, including the Langerhans cells in the epidermis and the dendritic cells in the dermis<sup><xref ref-type="bibr" rid="CR135">135</xref>,<xref ref-type="bibr" rid="CR136">136</xref></sup>. They can also be fabricated to deliver a range of biological vaccines, including inactivated and live attenuated viruses, VLPs and VNPs, protein subunits and DNA<sup><xref ref-type="bibr" rid="CR137">137</xref></sup>. Importantly, encapsulation in microneeedle patches increases the thermostability of these biologics, which is particularly important for vaccination in regions without proper cold chain infrastructure. Therefore, microneedles are perhaps the most promising device for widespread vaccine distribution and self-administration.</p><p id="Par51">Coated and dissolving microneedles have also been developed. Coated microneedles are designed by coating the surface of microneedles with antigen by dry-coating<sup><xref ref-type="bibr" rid="CR138">138</xref></sup> or layer-by-layer electrostatic deposition<sup><xref ref-type="bibr" rid="CR139">139</xref></sup>. Upon skin puncture, the coated antigen is immediately released to elicit an immunological response. For dry-coating, a stainless steel or silicon microneedle is dip-coated or dry-sprayed with a mixed solution of antigen and carboxymethylcellulose<sup><xref ref-type="bibr" rid="CR140">140</xref></sup>, polysaccharides<sup><xref ref-type="bibr" rid="CR141">141</xref></sup> or synthetic polymers<sup><xref ref-type="bibr" rid="CR142">142</xref></sup>. A disadvantage of this method is its limited loading capacity<sup><xref ref-type="bibr" rid="CR134">134</xref></sup>. However, loading can be increased by layer-by-layer electrostatic deposition; here, layers of oppositely charged polymers and proteins or nucleic acids are deposited in an alternating fashion<sup><xref ref-type="bibr" rid="CR139">139</xref></sup>.</p><p id="Par52">For the fabrication of dissolving microneedles, antigen is encapsulated within the microneedle tips, either in the bulk material or in microparticles. Upon insertion into the upper layers of the skin, the microneedles dissolve at rates dependent on the materials used<sup><xref ref-type="bibr" rid="CR143">143</xref></sup>. Each material has advantages and disadvantages (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>); for example, PVP<sup><xref ref-type="bibr" rid="CR117">117</xref></sup> rapidly dissolves upon contact with the interstitial fluid, which decreases the application time of the microneedles, but requires high doses owing to fast clearance rates. Alternatively, chitosan biodegrades slowly, thereby acting as a sustained-release depot. Chitosan microneedles have been shown to induce a more potent and long-lasting immune response compared with conventional intramuscular injection or injection with alum<sup><xref ref-type="bibr" rid="CR121">121</xref>,<xref ref-type="bibr" rid="CR144">144</xref></sup>. Dissolving microneedles are usually manufactured by micromoulding<sup><xref ref-type="bibr" rid="CR145">145</xref></sup>. Here, a mould is first filled with a polymer solution containing the antigen and then placed under vacuum or centrifuged to draw the solution into microcavities. The device is then allowed to dry and harden to form robust microneedle arrays. Water-soluble polymers, such as carboxymethyl cellulose and PVA, manufactured into microneedles under mild conditions, can protect encapsulated antigens from degradation<sup><xref ref-type="bibr" rid="CR146">146</xref>,<xref ref-type="bibr" rid="CR147">147</xref></sup>. Alternatively, dissolving microneedles can be fabricated by ultraviolet photo-polymerization of PVP within the mould<sup><xref ref-type="bibr" rid="CR117">117</xref></sup> or by high-temperature moulding<sup><xref ref-type="bibr" rid="CR148">148</xref></sup>; however, these processes can cause antigen degradation, because they require harsher conditions than solvent-based moulding.</p><p id="Par53">Microneedles with plant-produced antigens have already been shown to be effective. For example, a recombinant influenza VLP vaccine (along with a glucopyranosyl lipid adjuvant) administered by the NanoPass MicroJet microneedle, produced equal levels of haemagglutinin inhibition titres and seroprotection in humans, compared with intramuscular injection<sup><xref ref-type="bibr" rid="CR149">149</xref></sup>. In ferrets, the microneedle formulation led to 100% survival against a H5N1 challenge. Microneedle delivery also enables in situ vaccination; for example, microneedle-delivered CPMV showed greater potency in a mouse model of melanoma compared with intratumoral injection of CPMV, resulting in slower tumour growth and improved overall survival<sup><xref ref-type="bibr" rid="CR150">150</xref></sup>.</p></sec></sec></sec><sec id="Sec26"><title>Outlook</title><p id="Par54">The use of biologics in pharmaceutical applications will continue to grow as expression and purification technologies develop and mature. Plant molecular farming, in particular, is poised to make an impact on an array of applications, and new methodologies, such as the cookie technique, will continue to drive forward its use. Plant molecular farming is currently applied mainly in niche applications; however, recent developments and milestones, such as the production of millions of influenza vaccine doses in record time, has put a spotlight on this manufacturing platform<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. Following such successes, it is likely that molecular farming will gain in market share. We have just witnessed the worldwide efforts by laboratories and industry in pivoting their particular platforms and tools towards making vaccines, therapeutics or reagents for the ongoing COVID-19 pandemic or the Zika and Ebola epidemics<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR151">151</xref></sup>. Plant molecular farming requires less sophisticated infrastructure than does conventional vaccine production, and thus could be locally deployed in each region, therefore addressing vaccine rollout challenges. Moreover, plant molecular farming could enable the production of vaccines, therapeutics or reagents in space, either on a space station, or during months-long missions to Mars or other extraterrestrial destinations<sup><xref ref-type="bibr" rid="CR152">152</xref></sup>. The first grants supporting this technology have already been issued, for example, the NASA-funded use of transgenic lettuce and potato leaves to produce growth factors and hormones for astronauts to combat osteoporosis and other spaceflight-related health issues<sup><xref ref-type="bibr" rid="CR152">152</xref></sup>.</p><p id="Par55">However, expression levels in plant molecular farming must improve to levels similar to those achieved in mammalian or bacterial systems. Expression in bacterial systems was first achieved in the 1970s, ten years before expression in plants<sup><xref ref-type="bibr" rid="CR153">153</xref></sup>. This gap means that plant molecular farming lags behind other expression systems in terms of expression efficiency, which will be addressed by more efficient plant systems that can produce proteins at larger yields. In addition, downstream processing and purification of biologics need to improve, which remains challenging owing to the complexity of plant cells and tissues (plants produce 30% more solid debris than other expression systems and contain many contaminants, such as phenolics, which interfere with purification). The FDA Critical Path Report states that downstream processes were one of the key reasons that plant-made proteins routinely failed to transition into the clinic or industry<sup><xref ref-type="bibr" rid="CR154">154</xref></sup>. However, new methods, such as using acqueous two-phase partitioning systems, enzymatic hydrolysis, ultrasound, microwaves, pulsed electric fields, high-voltage electric discharge, ohmic heating, vacuum, subcritical and supercritical fluids, and hydrotropic and deep eutectic solvents are being developed to improve downstream processing of plant material<sup><xref ref-type="bibr" rid="CR155">155</xref>,<xref ref-type="bibr" rid="CR156">156</xref></sup>.</p><p id="Par56">Manufacturing of biologics by plant molecular farming is currently performed mainly at small scales by academic research laboratories and mid-sized pharmaceutical companies, at a lower cost than traditional fermentation-based expression systems (up to ten times and a hundred times lower than the production costs in <italic toggle="yes">E.</italic>&#8201;<italic toggle="yes">coli</italic> and CHO cells, respectively)<sup><xref ref-type="bibr" rid="CR157">157</xref></sup>. Once plant molecular farming reaches agricultural crop scales, the margins are expected to widen even further. The lower costs will help to offset the expensive costs of everyday laboratory research. Thus, molecular farming has the potential to reduce the price of recombinant therapeutics to levels similar to those of everyday over-the-counter medications. Molecular farming could also play a key part in producing biosimilars (biologics that are not identical to the original product, but are equally efficacious) to fabricate cheap pharmaceuticals or biological test reagents for all populations. In addition, decreasing the price of medications would also greatly reduce financial strains on the health-care system. For example, the monoclonal antibodies used in the alleviation of rheumatoid arthritis are currently unaffordable outside health-care systems in developed regions, although the majority of sufferers remain in underdeveloped regions.</p><p id="Par57">Future vaccines should be engineered to be free of cold chain restrictions, for example, by producing orally dosed vaccines and therapeutics in plants. Although the 1990s dream of simply &#8216;eating your vaccines&#8217; is unattainable (mainly owing to low yield of active ingredient and dose control), transgenic plants consumed by humans, such as potatoes, tomatoes and corn, can be used to not only deliver partially purified and quantified antigen, but also to protect the antigen within a heat-stable environment<sup><xref ref-type="bibr" rid="CR158">158</xref></sup>. The rigid plant cell wall can protect antigens from degradation within the harsh environment of the gastrointestinal system, while allowing antigen delivery<sup><xref ref-type="bibr" rid="CR159">159</xref></sup>. The use of orally dosed vaccines can help reduce cold chain requirements and obviate the need for antigen purification and downstream processing<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>. The amount of land required to vaccinate entire countries by orally dosed vaccines would also be minimal (for example, all of China could be vaccinated with only 40&#8201;hectares of land)<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>.</p><p id="Par58">Cold chain restrictions could also be mitigated by using new delivery agents, such as plant-made VNPs, that are intrinsically thermostable over a range of temperatures and pH levels, allowing their use in microneedle patches (which require high-temperature processing methods<sup><xref ref-type="bibr" rid="CR110">110</xref></sup>), and in oral vaccines (avoiding denaturation by the acidic gastrointestinal environment<sup><xref ref-type="bibr" rid="CR160">160</xref></sup>). Finally, new formulation chemistries and next-generation materials are anticipated to enhance formulation stability and improve delivery techniques. For example, the biomineralization of viral vaccines generates a mineral exterior, which improves the thermostability of the viral antigen<sup><xref ref-type="bibr" rid="CR161">161</xref></sup>. Furthermore, new combinations of excipients can further extend the half-life of vaccines<sup><xref ref-type="bibr" rid="CR162">162</xref></sup>. Finally, the formulation of biologics in microneedle patches and/or slow-release formulations has tremendous potential for the self-administration of medication.</p><p id="Par59">Thus, platform technologies to produce biologics from living systems continue to develop as new technologies become available, and next-generation nanotechnology and materials science have opened up opportunities in formulation chemistry and the administration of pharmaceuticals.</p></sec></body><back><fn-group><fn><p><bold>Peer review information</bold></p><p><italic toggle="yes">Nature Reviews Materials</italic> thanks Krishnendu Roy and the other, anonymous, reviewers for their contribution to the peer review of this work.</p></fn><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p><bold>Related links</bold></p><p><bold>The World Health Organization (WHO):</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/immunization/call-to-action_ipac-iscl.pdf">https://www.who.int/immunization/call-to-action_ipac-iscl.pdf</ext-link></p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was funded in part by the following grants from the NIH (U01-CA218292, R01-CA224605, R01-CA253615, R01-CA202-814 and R01-HL137674 to N.F.S.; R21AI161306 to N.F.S.), the American Cancer Society (128319-RSG-15-144-01-CDD to N.F.S.), the USDA (NIFA-2020-67021-31255 to N.F.S.), the CDMRP (W81XWH2010742 to N.F.S.), the NSF (RAPID CBET-2032196 to N.F.S.; RAPID CMMI-2027668 to N.F.S. and J.K.P.) as well as partially supported by the NSF through the UC San Diego Materials Research Science and Engineering Center (UCSD MRSEC), grant DMR-2011924 (to N.F.S., J.K.P., Y.C., D.C.). E.P.R. acknowledges research support from Medicago Inc. (Canada), the South African Medical Research Council and National Research Foundation, and the Poliomyelitis Research Foundation. E.C.K. was supported by the NIH T32EB005970 institutional training grant through the Clinician-Scientist Radiology Residency Program. E.O. was supported by the NIH 2T32 CA153915-06A1 institutional training grant through the Cancer Research in Nanotechnology San Diego Fellowship.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Y.C. wrote the first drafts of the manuscript, researched data for the article and prepared figures; D.C. wrote the sections focusing on vaccine administration technology and prepared figures; E.C.K. wrote the sections focusing on biologics and background on vaccines and prepared figures; E.O. wrote the sections focusing on the cold chain and vaccine distribution and prepared figures; S.S. wrote the sections focusing on molecular farming for plant viral nanoparticles and prepared figures. E.P.R. and N.F.S. wrote the section on plant molecular farming. N.F.S. and Y.C. prepared the final version of the manuscript. N.F.S. and J.K.P. conceived the manuscript and were in charge of overall direction and planning. All authors reviewed and edited the final version of the manuscript.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par60">N.F.S. and J.K.P. are co-founders of and have a financial interest with Mosaic IE Inc. E.P.R. has a financial interest in Cape Bio Pharms Ltd in Cape Town. All other authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurevich</surname><given-names>EV</given-names></name><name name-style="western"><surname>Gurevich</surname><given-names>VV</given-names></name></person-group><article-title>Beyond traditional pharmacology: new tools and approaches</article-title><source>Br. J. Pharmacol.</source><year>2015</year><volume>172</volume><fpage>3229</fpage><lpage>3241</lpage><pub-id pub-id-type="doi">10.1111/bph.13066</pub-id><pub-id pub-id-type="pmid">25572005</pub-id><pub-id pub-id-type="pmcid">PMC4500362</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>J</given-names></name><etal/></person-group><article-title>Increased MSX level improves biological productivity and production stability in multiple recombinant GS CHO cell lines</article-title><source>Eng. Life Sci.</source><year>2020</year><volume>20</volume><fpage>112</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1002/elsc.201900124</pub-id><pub-id pub-id-type="pmid">32874175</pub-id><pub-id pub-id-type="pmcid">PMC7447880</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>JC</given-names></name><name name-style="western"><surname>Chan</surname><given-names>AT</given-names></name></person-group><article-title>Biologics and biosimilars: what, why and how?</article-title><source>ESMO Open</source><year>2017</year><volume>2</volume><fpage>e000180</fpage><pub-id pub-id-type="doi">10.1136/esmoopen-2017-000180</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orenstein</surname><given-names>WA</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R</given-names></name></person-group><article-title>Simply put: vaccination saves lives</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>4031</fpage><lpage>4033</lpage><pub-id pub-id-type="doi">10.1073/pnas.1704507114</pub-id><pub-id pub-id-type="pmid">28396427</pub-id><pub-id pub-id-type="pmcid">PMC5402432</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenwood</surname><given-names>B</given-names></name></person-group><article-title>The contribution of vaccination to global health: past, present and future</article-title><source>Phil. Trans. R. Soc. Lond. B</source><year>2014</year><volume>369</volume><fpage>20130433</fpage><pub-id pub-id-type="doi">10.1098/rstb.2013.0433</pub-id><pub-id pub-id-type="pmid">24821919</pub-id><pub-id pub-id-type="pmcid">PMC4024226</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozawa</surname><given-names>S</given-names></name><etal/></person-group><article-title>Return on investment from childhood immunization in low- and middle-income countries, 2011&#8211;20</article-title><source>Health Aff.</source><year>2016</year><volume>35</volume><fpage>199</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1377/hlthaff.2015.1086</pub-id><pub-id pub-id-type="pmid">26858370</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barta</surname><given-names>A</given-names></name><etal/></person-group><article-title>The expression of a nopaline synthase &#8212; human growth hormone chimaeric gene in transformed tobacco and sunflower callus tissue</article-title><source>Plant. Mol. Biol.</source><year>1986</year><volume>6</volume><fpage>347</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1007/BF00034942</pub-id><pub-id pub-id-type="pmid">24307385</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18&#8211;64 years) and older adults (&#8805;65 years): two multicentre, randomised phase 3 trials</article-title><source>Lancet</source><year>2020</year><volume>396</volume><fpage>1491</fpage><lpage>1503</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32014-6</pub-id><pub-id pub-id-type="pmid">33065035</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">[No authors listed.] In brief: Taliglucerase (Elelyso) for Gaucher disease. <italic toggle="yes">Med. Lett. Drugs Ther</italic>. <bold>54</bold>, 56 (2012). <bold>This paper describes Elelyso, the first plant-derived human pharmaceutical on the market</bold>.<pub-id pub-id-type="pmid">22966489</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rybicki</surname><given-names>EP</given-names></name></person-group><article-title>Plant molecular farming of virus-like nanoparticles as vaccines and reagents</article-title><source>WIREs Nanomed. Nanobiol.</source><year>2020</year><volume>12</volume><fpage>e1587</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/wnan.1587</pub-id><pub-id pub-id-type="pmid">31486296</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>YH</given-names></name><name name-style="western"><surname>Beiss</surname><given-names>V</given-names></name><name name-style="western"><surname>Fiering</surname><given-names>SN</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>NF</given-names></name></person-group><article-title>COVID-19 vaccine frontrunners and their nanotechnology design</article-title><source>ACS Nano.</source><year>2020</year><volume>14</volume><fpage>12522</fpage><lpage>12537</lpage><pub-id pub-id-type="doi">10.1021/acsnano.0c07197</pub-id><pub-id pub-id-type="pmid">33034449</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z</given-names></name><name name-style="western"><surname>Williams</surname><given-names>RO</given-names></name></person-group><article-title>The COVID-19 vaccine race: challenges and opportunities in vaccine formulation</article-title><source>AAPS PharmSciTech.</source><year>2020</year><volume>21</volume><fpage>225</fpage><pub-id pub-id-type="doi">10.1208/s12249-020-01744-7</pub-id><pub-id pub-id-type="pmid">32761294</pub-id><pub-id pub-id-type="pmcid">PMC7405756</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plotkin</surname><given-names>S</given-names></name></person-group><article-title>History of vaccination</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>12283</fpage><lpage>12287</lpage><pub-id pub-id-type="doi">10.1073/pnas.1400472111</pub-id><pub-id pub-id-type="pmid">25136134</pub-id><pub-id pub-id-type="pmcid">PMC4151719</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoenig</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>AC</given-names></name><name name-style="western"><surname>Dickinson</surname><given-names>GM</given-names></name></person-group><article-title>The early use of Pasteur&#8217;s rabies vaccine in the United States</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>4578</fpage><lpage>4581</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.05.016</pub-id><pub-id pub-id-type="pmid">29921493</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enders</surname><given-names>JF</given-names></name><name name-style="western"><surname>Weller</surname><given-names>TH</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>FC</given-names></name></person-group><article-title>Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues</article-title><source>Science</source><year>1949</year><volume>109</volume><fpage>85</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1126/science.109.2822.85</pub-id><pub-id pub-id-type="pmid">17794160</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valenzuela</surname><given-names>P</given-names></name><name name-style="western"><surname>Medina</surname><given-names>A</given-names></name><name name-style="western"><surname>Rutter</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Ammerer</surname><given-names>G</given-names></name><name name-style="western"><surname>Hall</surname><given-names>BD</given-names></name></person-group><article-title>Synthesis and assembly of hepatitis B virus surface antigen particles in yeast</article-title><source>Nature</source><year>1982</year><volume>298</volume><fpage>347</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1038/298347a0</pub-id><pub-id pub-id-type="pmid">7045698</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>SP</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>V</given-names></name></person-group><article-title>COVID-19 vaccine: a comprehensive status report</article-title><source>Virus Res.</source><year>2020</year><volume>288</volume><fpage>198114</fpage><pub-id pub-id-type="doi">10.1016/j.virusres.2020.198114</pub-id><pub-id pub-id-type="pmid">32800805</pub-id><pub-id pub-id-type="pmcid">PMC7423510</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delany</surname><given-names>I</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>E</given-names></name></person-group><article-title>Vaccines for the 21st century</article-title><source>EMBO Mol. Med.</source><year>2014</year><volume>6</volume><fpage>708</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1002/emmm.201403876</pub-id><pub-id pub-id-type="pmid">24803000</pub-id><pub-id pub-id-type="pmcid">PMC4203350</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrosky</surname><given-names>E</given-names></name><etal/></person-group><article-title>Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices</article-title><source>MMWR</source><year>2015</year><volume>64</volume><fpage>300</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">25811679</pub-id><pub-id pub-id-type="pmcid">PMC4584883</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>YH</given-names></name><name name-style="western"><surname>Seong</surname><given-names>BL</given-names></name></person-group><article-title>The quest for a truly universal influenza vaccine</article-title><source>Front. Cell Infect. Microbiol.</source><year>2019</year><volume>9</volume><fpage>344</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2019.00344</pub-id><pub-id pub-id-type="pmid">31649895</pub-id><pub-id pub-id-type="pmcid">PMC6795694</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kines</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><fpage>e0120797</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0120797</pub-id><pub-id pub-id-type="pmid">25785935</pub-id><pub-id pub-id-type="pmcid">PMC4364728</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shao</surname><given-names>S</given-names></name><name name-style="western"><surname>Ortega-Rivera</surname><given-names>OA</given-names></name><name name-style="western"><surname>Ray</surname><given-names>SK</given-names></name><name name-style="western"><surname>Pokorski</surname><given-names>J</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>NF</given-names></name></person-group><article-title>A scalable manufacturing approach to single dose vaccination against HPV</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><fpage>66</fpage><pub-id pub-id-type="doi">10.3390/vaccines9010066</pub-id><pub-id pub-id-type="pmid">33478147</pub-id><pub-id pub-id-type="pmcid">PMC7835769</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenthal</surname><given-names>KS</given-names></name><name name-style="western"><surname>Carambula</surname><given-names>R</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>DH</given-names></name></person-group><article-title>Why don&#8217;t we have a vaccine against autoimmune diseases? &#8212; a review</article-title><source>J. Clin. Cell Immunol.</source><year>2019</year><volume>10</volume><fpage>574</fpage><pub-id pub-id-type="pmid">31328022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4172/2155-9899.1000574</pub-id><pub-id pub-id-type="pmcid">PMC6640150</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Z-Y</given-names></name></person-group><article-title>The ways of isolating neoantigen-specific T cells</article-title><source>Front. Oncol.</source><year>2020</year><volume>10</volume><fpage>1347</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.01347</pub-id><pub-id pub-id-type="pmid">32850430</pub-id><pub-id pub-id-type="pmcid">PMC7431921</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voysey</surname><given-names>M</given-names></name><etal/></person-group><article-title>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK</article-title><source>Lancet</source><year>2020</year><volume>397</volume><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32661-1</pub-id><pub-id pub-id-type="pmid">33306989</pub-id><pub-id pub-id-type="pmcid">PMC7723445</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baeshen</surname><given-names>NA</given-names></name><etal/></person-group><article-title>Cell factories for insulin production</article-title><source>Microb. Cell Fact.</source><year>2014</year><volume>13</volume><fpage>141</fpage><pub-id pub-id-type="doi">10.1186/s12934-014-0141-0</pub-id><pub-id pub-id-type="pmid">25270715</pub-id><pub-id pub-id-type="pmcid">PMC4203937</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hammond</surname><given-names>GW</given-names></name><etal/></person-group><article-title>Comparison of immunogenicity of two yeast-derived recombinant hepatitis B vaccines</article-title><source>Vaccine</source><year>1991</year><volume>9</volume><fpage>97</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(91)90263-6</pub-id><pub-id pub-id-type="pmid">1829306</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Owczarek</surname><given-names>B</given-names></name><name name-style="western"><surname>Gerszberg</surname><given-names>A</given-names></name><name name-style="western"><surname>Hnatuszko-Konka</surname><given-names>K</given-names></name></person-group><article-title>A brief reminder of systems of production and chromatography-based recovery of recombinant protein biopharmaceuticals</article-title><source>Biomed. Res. Int.</source><year>2019</year><volume>2019</volume><fpage>4216060</fpage><pub-id pub-id-type="doi">10.1155/2019/4216060</pub-id><pub-id pub-id-type="pmid">30729123</pub-id><pub-id pub-id-type="pmcid">PMC6341259</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Overton</surname><given-names>TW</given-names></name></person-group><article-title>Recombinant protein production in bacterial hosts</article-title><source>Drug Discov. Today</source><year>2014</year><volume>19</volume><fpage>590</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2013.11.008</pub-id><pub-id pub-id-type="pmid">24246684</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrer-Miralles</surname><given-names>N</given-names></name><name name-style="western"><surname>Domingo-Esp&#237;n</surname><given-names>J</given-names></name><name name-style="western"><surname>Corchero</surname><given-names>JL</given-names></name><name name-style="western"><surname>V&#225;zquez</surname><given-names>E</given-names></name><name name-style="western"><surname>Villaverde</surname><given-names>A</given-names></name></person-group><article-title>Microbial factories for recombinant pharmaceuticals</article-title><source>Microb. Cell Fact.</source><year>2009</year><volume>8</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/1475-2859-8-17</pub-id><pub-id pub-id-type="pmid">19317892</pub-id><pub-id pub-id-type="pmcid">PMC2669800</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makrides</surname><given-names>SC</given-names></name></person-group><article-title>Strategies for achieving high-level expression of genes in <italic toggle="yes">Escherichia coli</italic></article-title><source>Microbiol. Mol. Biol. Rev.</source><year>1996</year><volume>60</volume><fpage>512</fpage><lpage>538</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mr.60.3.512-538.1996</pub-id><pub-id pub-id-type="pmcid">PMC239455</pub-id><pub-id pub-id-type="pmid">8840785</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tripathi</surname><given-names>NK</given-names></name><name name-style="western"><surname>Shrivastava</surname><given-names>A</given-names></name></person-group><article-title>Recent developments in bioprocessing of recombinant proteins: expression hosts and process development</article-title><source>Front. Bioeng. Biotechnol.</source><year>2019</year><volume>7</volume><fpage>420</fpage><pub-id pub-id-type="doi">10.3389/fbioe.2019.00420</pub-id><pub-id pub-id-type="pmid">31921823</pub-id><pub-id pub-id-type="pmcid">PMC6932962</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>JY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y-G</given-names></name><name name-style="western"><surname>Lee</surname><given-names>GM</given-names></name></person-group><article-title>CHO cells in biotechnology for production of recombinant proteins: current state and further potential</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2012</year><volume>93</volume><fpage>917</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1007/s00253-011-3758-5</pub-id><pub-id pub-id-type="pmid">22159888</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dumont</surname><given-names>J</given-names></name><name name-style="western"><surname>Euwart</surname><given-names>D</given-names></name><name name-style="western"><surname>Mei</surname><given-names>B</given-names></name><name name-style="western"><surname>Estes</surname><given-names>S</given-names></name><name name-style="western"><surname>Kshirsagar</surname><given-names>R</given-names></name></person-group><article-title>Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives</article-title><source>Crit. Rev. Biotechnol.</source><year>2016</year><volume>36</volume><fpage>1110</fpage><lpage>1122</lpage><pub-id pub-id-type="doi">10.3109/07388551.2015.1084266</pub-id><pub-id pub-id-type="pmid">26383226</pub-id><pub-id pub-id-type="pmcid">PMC5152558</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghaderi</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Hurtado-Ziola</surname><given-names>N</given-names></name><name name-style="western"><surname>Varki</surname><given-names>A</given-names></name></person-group><article-title>Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation</article-title><source>Biotechnol. Genet. Eng. Rev.</source><year>2012</year><volume>28</volume><fpage>147</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.5661/bger-28-147</pub-id><pub-id pub-id-type="pmid">22616486</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jefferis</surname><given-names>R</given-names></name></person-group><article-title>Posttranslational modifications and the immunogenicity of biotherapeutics</article-title><source>J. Immunol. Res.</source><year>2016</year><volume>2016</volume><fpage>5358272</fpage><pub-id pub-id-type="doi">10.1155/2016/5358272</pub-id><pub-id pub-id-type="pmid">27191002</pub-id><pub-id pub-id-type="pmcid">PMC4848426</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ikonomou</surname><given-names>L</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>Y-J</given-names></name><name name-style="western"><surname>Agathos</surname><given-names>SN</given-names></name></person-group><article-title>Insect cell culture for industrial production of recombinant proteins</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2003</year><volume>62</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/s00253-003-1223-9</pub-id><pub-id pub-id-type="pmid">12733003</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Felberbaum</surname><given-names>RS</given-names></name></person-group><article-title>The baculovirus expression vector system: a commercial manufacturing platform for viral vaccines and gene therapy vectors</article-title><source>Biotechnol. J.</source><year>2015</year><volume>10</volume><fpage>702</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1002/biot.201400438</pub-id><pub-id pub-id-type="pmid">25800821</pub-id><pub-id pub-id-type="pmcid">PMC7159335</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajaram</surname><given-names>S</given-names></name><name name-style="western"><surname>Boikos</surname><given-names>C</given-names></name><name name-style="western"><surname>Gelone</surname><given-names>DK</given-names></name><name name-style="western"><surname>Gandhi</surname><given-names>A</given-names></name></person-group><article-title>Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing</article-title><source>Ther. Adv. Vaccines Immunother.</source><year>2020</year><pub-id pub-id-type="doi">10.1177/2515135520908121</pub-id><pub-id pub-id-type="pmcid">PMC7036483</pub-id><pub-id pub-id-type="pmid">32128506</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Izurieta</surname><given-names>HS</given-names></name><etal/></person-group><article-title>Relative effectiveness of cell-cultured and egg-based influenza vaccines among elderly persons in the United States, 2017&#8211;2018</article-title><source>J. Infect. Dis.</source><year>2019</year><volume>220</volume><fpage>1255</fpage><lpage>1264</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy716</pub-id><pub-id pub-id-type="pmid">30561688</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gregersen</surname><given-names>J-P</given-names></name></person-group><article-title>A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>3297</fpage><lpage>3304</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.03.076</pub-id><pub-id pub-id-type="pmid">18468737</pub-id><pub-id pub-id-type="pmcid">PMC7115387</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rybicki</surname><given-names>EP</given-names></name></person-group><article-title>Plant-made vaccines for humans and animals</article-title><source>Plant. Biotechnol. J.</source><year>2010</year><volume>8</volume><fpage>620</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1111/j.1467-7652.2010.00507.x</pub-id><pub-id pub-id-type="pmid">20233333</pub-id><pub-id pub-id-type="pmcid">PMC7167690</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pujol</surname><given-names>M</given-names></name><etal/></person-group><article-title>An integral approach towards a practical application for a plant-made monoclonal antibody in vaccine purification</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>1833</fpage><lpage>1837</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.11.023</pub-id><pub-id pub-id-type="pmid">15734051</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liew</surname><given-names>PS</given-names></name><name name-style="western"><surname>Hair-Bejo</surname><given-names>M</given-names></name></person-group><article-title>Farming of plant-based veterinary vaccines and their applications for disease prevention in animals</article-title><source>Adv. Virol.</source><year>2015</year><volume>2015</volume><fpage>936940</fpage><pub-id pub-id-type="doi">10.1155/2015/936940</pub-id><pub-id pub-id-type="pmid">26351454</pub-id><pub-id pub-id-type="pmcid">PMC4550766</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lico</surname><given-names>C</given-names></name><etal/></person-group><article-title>Plant molecular farming as a strategy against COVID-19 &#8212; the Italian perspective</article-title><source>Front. Plant. Sci.</source><year>2020</year><volume>11</volume><fpage>609910</fpage><pub-id pub-id-type="doi">10.3389/fpls.2020.609910</pub-id><pub-id pub-id-type="pmid">33381140</pub-id><pub-id pub-id-type="pmcid">PMC7768017</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahmood</surname><given-names>N</given-names></name><name name-style="western"><surname>Nasir</surname><given-names>SB</given-names></name><name name-style="western"><surname>Hefferon</surname><given-names>K</given-names></name></person-group><article-title>Plant-based drugs and vaccines for COVID-19</article-title><source>Vaccines</source><year>2020</year><volume>9</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.3390/vaccines9010015</pub-id><pub-id pub-id-type="pmid">33396667</pub-id><pub-id pub-id-type="pmcid">PMC7823519</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Phase 1 trial of a candidate recombinant virus-like particle vaccine for Covid-19 disease produced in plants. Preprint at</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.11.04.20226282</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kyriakidis</surname><given-names>NC</given-names></name><name name-style="western"><surname>L&#243;pez-Cort&#233;s</surname><given-names>A</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>EV</given-names></name><name name-style="western"><surname>Grimaldos</surname><given-names>AB</given-names></name><name name-style="western"><surname>Prado</surname><given-names>EO</given-names></name></person-group><article-title>SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates</article-title><source>npj Vaccines</source><year>2021</year><volume>6</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1038/s41541-021-00292-w</pub-id><pub-id pub-id-type="pmid">33619260</pub-id><pub-id pub-id-type="pmcid">PMC7900244</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doron</surname><given-names>L</given-names></name><name name-style="western"><surname>Segal</surname><given-names>N</given-names></name><name name-style="western"><surname>Shapira</surname><given-names>M</given-names></name></person-group><article-title>Transgene expression in microalgae &#8212; from tools to applications</article-title><source>Front. Plant. Sci.</source><year>2016</year><volume>7</volume><fpage>505</fpage><pub-id pub-id-type="doi">10.3389/fpls.2016.00505</pub-id><pub-id pub-id-type="pmid">27148328</pub-id><pub-id pub-id-type="pmcid">PMC4840263</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dyo</surname><given-names>YM</given-names></name><name name-style="western"><surname>Purton</surname><given-names>S</given-names></name></person-group><article-title>The algal chloroplast as a synthetic biology platform for production of therapeutic proteins</article-title><source>Microbiology</source><year>2018</year><volume>164</volume><fpage>113</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1099/mic.0.000599</pub-id><pub-id pub-id-type="pmid">29297850</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taunt</surname><given-names>HN</given-names></name><name name-style="western"><surname>Stoffels</surname><given-names>L</given-names></name><name name-style="western"><surname>Purton</surname><given-names>S</given-names></name></person-group><article-title>Green biologics: the algal chloroplast as a platform for making biopharmaceuticals</article-title><source>Bioengineered</source><year>2018</year><volume>9</volume><fpage>48</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1080/21655979.2017.1377867</pub-id><pub-id pub-id-type="pmid">28892417</pub-id><pub-id pub-id-type="pmcid">PMC5972929</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gasdaska</surname><given-names>J</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>D</given-names></name><name name-style="western"><surname>Dickey</surname><given-names>L</given-names></name></person-group><article-title>Advantages of therapeutic protein production in the aquatic plant <italic toggle="yes">Lemna</italic></article-title><source>BioProcess. J.</source><year>2003</year><volume>2</volume><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.12665/J22.Gasdaska</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reski</surname><given-names>R</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>J</given-names></name><name name-style="western"><surname>Decker</surname><given-names>EL</given-names></name></person-group><article-title>Moss-made pharmaceuticals: from bench to bedside</article-title><source>Plant. Biotechnol. J.</source><year>2015</year><volume>13</volume><fpage>1191</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1111/pbi.12401</pub-id><pub-id pub-id-type="pmid">26011014</pub-id><pub-id pub-id-type="pmcid">PMC4736463</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>KY</given-names></name><name name-style="western"><surname>Wi</surname><given-names>SJ</given-names></name></person-group><article-title>Potential of plants to produce recombinant protein products</article-title><source>J. Plant. Biol.</source><year>2016</year><volume>59</volume><fpage>559</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1007/s12374-016-0482-9</pub-id><pub-id pub-id-type="pmid">32288513</pub-id><pub-id pub-id-type="pmcid">PMC7101786</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rybicki</surname><given-names>EP</given-names></name></person-group><article-title>Plant-produced vaccines: promise and reality</article-title><source>Drug Discov. Today</source><year>2009</year><volume>14</volume><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2008.10.002</pub-id><pub-id pub-id-type="pmid">18983932</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tschofen</surname><given-names>M</given-names></name><name name-style="western"><surname>Knopp</surname><given-names>D</given-names></name><name name-style="western"><surname>Hood</surname><given-names>E</given-names></name><name name-style="western"><surname>St&#246;ger</surname><given-names>E</given-names></name></person-group><article-title>Plant molecular farming: much more than medicines</article-title><source>Annu. Rev. Anal. Chem.</source><year>2016</year><volume>9</volume><fpage>271</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1146/annurev-anchem-071015-041706</pub-id><pub-id pub-id-type="pmid">27049632</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>K-B</given-names></name><etal/></person-group><article-title>Development of systems for the production of plant-derived biopharmaceuticals</article-title><source>Plants</source><year>2019</year><volume>9</volume><fpage>30</fpage><pub-id pub-id-type="doi">10.3390/plants9010030</pub-id><pub-id pub-id-type="pmid">31878277</pub-id><pub-id pub-id-type="pmcid">PMC7020158</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaaltiel</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher&#8217;s disease using a plant cell system</article-title><source>Plant. Biotechnol. J.</source><year>2007</year><volume>5</volume><fpage>579</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1111/j.1467-7652.2007.00263.x</pub-id><pub-id pub-id-type="pmid">17524049</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Landry</surname><given-names>N</given-names></name><etal/></person-group><article-title>Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><fpage>e15559</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0015559</pub-id><pub-id pub-id-type="pmid">21203523</pub-id><pub-id pub-id-type="pmcid">PMC3008737</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Margolin</surname><given-names>E</given-names></name><etal/></person-group><article-title>Co-expression of human calreticulin significantly improves the production of HIV gp140 and other viral glycoproteins in plants</article-title><source>Plant. Biotechnol. J.</source><year>2020</year><volume>18</volume><fpage>2109</fpage><lpage>2117</lpage><pub-id pub-id-type="doi">10.1111/pbi.13369</pub-id><pub-id pub-id-type="pmid">32096288</pub-id><pub-id pub-id-type="pmcid">PMC7540014</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merlin</surname><given-names>M</given-names></name><name name-style="western"><surname>Gecchele</surname><given-names>E</given-names></name><name name-style="western"><surname>Capaldi</surname><given-names>S</given-names></name><name name-style="western"><surname>Pezzotti</surname><given-names>M</given-names></name><name name-style="western"><surname>Avesani</surname><given-names>L</given-names></name></person-group><article-title>Comparative evaluation of recombinant protein production in different biofactories: the green perspective</article-title><source>BioMed. Res. Int.</source><year>2014</year><volume>2014</volume><fpage>136419</fpage><pub-id pub-id-type="doi">10.1155/2014/136419</pub-id><pub-id pub-id-type="pmid">24745008</pub-id><pub-id pub-id-type="pmcid">PMC3972949</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gunasekaran</surname><given-names>B</given-names></name><name name-style="western"><surname>Gothandam</surname><given-names>KM</given-names></name></person-group><article-title>A review on edible vaccines and their prospects</article-title><source>Braz. J. Med. Biol. Res.</source><year>2020</year><volume>53</volume><fpage>e8749</fpage><pub-id pub-id-type="doi">10.1590/1414-431x20198749</pub-id><pub-id pub-id-type="pmid">31994600</pub-id><pub-id pub-id-type="pmcid">PMC6984374</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naupu</surname><given-names>PN</given-names></name><name name-style="western"><surname>van Zyl</surname><given-names>AR</given-names></name><name name-style="western"><surname>Rybicki</surname><given-names>EP</given-names></name><name name-style="western"><surname>Hitzeroth</surname><given-names>II</given-names></name></person-group><article-title>Immunogenicity of plant-produced human papillomavirus (HPV) virus-like particles (VLPs)</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><fpage>740</fpage><pub-id pub-id-type="doi">10.3390/vaccines8040740</pub-id><pub-id pub-id-type="pmid">33291259</pub-id><pub-id pub-id-type="pmcid">PMC7762164</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>H</given-names></name><etal/></person-group><article-title>A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>1846</fpage><lpage>1852</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.02.073</pub-id><pub-id pub-id-type="pmid">29490880</pub-id><pub-id pub-id-type="pmcid">PMC5851867</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ponndorf</surname><given-names>D</given-names></name><etal/></person-group><article-title>Plant-made dengue virus-like particles produced by co-expression of structural and non-structural proteins induce a humoral immune response in mice</article-title><source>Plant. Biotechnol. J.</source><year>2021</year><volume>19</volume><fpage>745</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1111/pbi.13501</pub-id><pub-id pub-id-type="pmid">33099859</pub-id><pub-id pub-id-type="pmcid">PMC8051607</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamprecht</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Production of human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>20431</fpage><pub-id pub-id-type="doi">10.1038/srep20431</pub-id><pub-id pub-id-type="pmid">26853456</pub-id><pub-id pub-id-type="pmcid">PMC4745065</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Maharaj</surname><given-names>PD</given-names></name><name name-style="western"><surname>Mallajosyula</surname><given-names>JK</given-names></name><name name-style="western"><surname>McCormick</surname><given-names>AA</given-names></name><name name-style="western"><surname>Kearney</surname><given-names>CM</given-names></name></person-group><article-title><italic toggle="yes">In planta</italic> production of flock house virus transencapsidated RNA and its potential use as a vaccine</article-title><source>Mol. Biotechnol.</source><year>2015</year><volume>57</volume><fpage>325</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1007/s12033-014-9826-1</pub-id><pub-id pub-id-type="pmid">25432792</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name></person-group><article-title>On the way to commercializing plant cell culture platform for biopharmaceuticals: present status and prospect</article-title><source>Pharm. Bioprocess.</source><year>2014</year><volume>2</volume><fpage>499</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.4155/pbp.14.32</pub-id><pub-id pub-id-type="pmid">25621170</pub-id><pub-id pub-id-type="pmcid">PMC4303569</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rademacher</surname><given-names>T</given-names></name><etal/></person-group><article-title>Plant cell packs: a scalable platform for recombinant protein production and metabolic engineering</article-title><source>Plant. Biotechnol. J.</source><year>2019</year><volume>17</volume><fpage>1560</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.1111/pbi.13081</pub-id><pub-id pub-id-type="pmid">30672078</pub-id><pub-id pub-id-type="pmcid">PMC6662111</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gengenbach</surname><given-names>BB</given-names></name><name name-style="western"><surname>Opdensteinen</surname><given-names>P</given-names></name><name name-style="western"><surname>Buyel</surname><given-names>JF</given-names></name></person-group><article-title>Robot cookies &#8212; plant cell packs as an automated high-throughput screening platform based on transient expression</article-title><source>Front. Bioeng. Biotechnol.</source><year>2020</year><volume>8</volume><fpage>393</fpage><pub-id pub-id-type="doi">10.3389/fbioe.2020.00393</pub-id><pub-id pub-id-type="pmid">32432097</pub-id><pub-id pub-id-type="pmcid">PMC7214789</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pishko</surname><given-names>A</given-names></name><name name-style="western"><surname>Nasta</surname><given-names>SD</given-names></name></person-group><article-title>The role of novel immunotherapies in non-Hodgkin lymphoma</article-title><source>Transl. Cancer Res.</source><year>2017</year><volume>6</volume><fpage>93</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.21037/tcr.2017.01.08</pub-id><pub-id pub-id-type="pmid">28955654</pub-id><pub-id pub-id-type="pmcid">PMC5612371</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCormick</surname><given-names>AA</given-names></name></person-group><article-title>Tobacco derived cancer vaccines for non-Hodgkin&#8217;s lymphoma: perspectives and progress</article-title><source>Hum. Vaccin.</source><year>2011</year><volume>7</volume><fpage>305</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.4161/hv.7.3.14163</pub-id><pub-id pub-id-type="pmid">21346416</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tus&#233;</surname><given-names>D</given-names></name><etal/></person-group><article-title>Clinical safety and immunogenicity of tumor-targeted, plant-made Id-KLH conjugate vaccines for follicular lymphoma</article-title><source>Biomed. Res. Int.</source><year>2015</year><volume>2015</volume><fpage>648143</fpage><pub-id pub-id-type="doi">10.1155/2015/648143</pub-id><pub-id pub-id-type="pmid">26425548</pub-id><pub-id pub-id-type="pmcid">PMC4575747</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rybicki</surname><given-names>EP</given-names></name></person-group><article-title>Plant-made vaccines and reagents for the One Health initiative</article-title><source>Hum. Vaccin. Immunother.</source><year>2017</year><volume>13</volume><fpage>2912</fpage><lpage>2917</lpage><pub-id pub-id-type="doi">10.1080/21645515.2017.1356497</pub-id><pub-id pub-id-type="pmid">28846485</pub-id><pub-id pub-id-type="pmcid">PMC5718809</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atkinson</surname><given-names>R</given-names></name><name name-style="western"><surname>Burt</surname><given-names>F</given-names></name><name name-style="western"><surname>Rybicki</surname><given-names>EP</given-names></name><name name-style="western"><surname>Meyers</surname><given-names>AE</given-names></name></person-group><article-title>Plant-produced Crimean&#8211;Congo haemorrhagic fever virus nucleoprotein for use in indirect ELISA</article-title><source>J. Virol. Methods</source><year>2016</year><volume>236</volume><fpage>170</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2016.07.025</pub-id><pub-id pub-id-type="pmid">27474493</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mbewana</surname><given-names>S</given-names></name><etal/></person-group><article-title>Expression of Rift Valley fever virus N-protein in <italic toggle="yes">Nicotiana benthamiana</italic> for use as a diagnostic antigen</article-title><source>BMC Biotechnol.</source><year>2018</year><volume>18</volume><fpage>77</fpage><pub-id pub-id-type="doi">10.1186/s12896-018-0489-z</pub-id><pub-id pub-id-type="pmid">30537953</pub-id><pub-id pub-id-type="pmcid">PMC6290525</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><mixed-citation publication-type="other">Margolin, E. et al. Calreticulin co-expression supports high level production of a recombinant SARS-CoV-2 spike mimetic in Nicotiana benthamiana. Preprint at <italic toggle="yes">bioRxiv</italic>10.1101/2020.06.14.150458 (2020).</mixed-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steele</surname><given-names>JFC</given-names></name><etal/></person-group><article-title>Synthetic plant virology for nanobiotechnology and nanomedicine</article-title><source>Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.</source><year>2017</year><volume>9</volume><fpage>e1447</fpage><pub-id pub-id-type="doi">10.1002/wnan.1447</pub-id><pub-id pub-id-type="pmid">28078770</pub-id><pub-id pub-id-type="pmcid">PMC5484280</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Czapar</surname><given-names>AE</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>NF</given-names></name></person-group><article-title>Plant viruses and bacteriophages for drug delivery in medicine and biotechnology</article-title><source>Curr. Opin. Chem. Biol.</source><year>2017</year><volume>38</volume><fpage>108</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2017.03.013</pub-id><pub-id pub-id-type="pmid">28426952</pub-id><pub-id pub-id-type="pmcid">PMC5488792</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shoeb</surname><given-names>E</given-names></name><name name-style="western"><surname>Hefferon</surname><given-names>K</given-names></name></person-group><article-title>Future of cancer immunotherapy using plant virus-based nanoparticles</article-title><source>Future Sci. OA</source><year>2019</year><volume>5</volume><fpage>FSO401</fpage><pub-id pub-id-type="doi">10.2144/fsoa-2019-0001</pub-id><pub-id pub-id-type="pmid">31428448</pub-id><pub-id pub-id-type="pmcid">PMC6695527</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Biomimetic virus-like particles as severe acute respiratory syndrome coronavirus 2 diagnostic tools</article-title><source>ACS Nano</source><year>2020</year><volume>15</volume><fpage>1259</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.1021/acsnano.0c08430</pub-id><pub-id pub-id-type="pmid">33237727</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>YH</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>NF</given-names></name></person-group><article-title>Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications</article-title><source>Adv. Drug Deliv. Rev.</source><year>2020</year><volume>156</volume><fpage>214</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.06.024</pub-id><pub-id pub-id-type="pmid">32603813</pub-id><pub-id pub-id-type="pmcid">PMC7320870</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wi</surname><given-names>S</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>IS</given-names></name><name name-style="western"><surname>Jo</surname><given-names>BH</given-names></name></person-group><article-title>Engineering a plant viral coat protein for in vitro hybrid self-assembly of CO<sub>2</sub>-capturing catalytic nanofilaments</article-title><source>Biomacromolecules</source><year>2020</year><volume>21</volume><fpage>3847</fpage><lpage>3856</lpage><pub-id pub-id-type="doi">10.1021/acs.biomac.0c00925</pub-id><pub-id pub-id-type="pmid">32786518</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Physalis mottle virus-like nanoparticles for targeted cancer imaging</article-title><source>ACS Appl. Mater. Interfaces</source><year>2019</year><volume>11</volume><fpage>18213</fpage><lpage>18223</lpage><pub-id pub-id-type="doi">10.1021/acsami.9b03956</pub-id><pub-id pub-id-type="pmid">31074602</pub-id><pub-id pub-id-type="pmcid">PMC7060085</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chariou</surname><given-names>PL</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>NF</given-names></name></person-group><article-title>Delivery of pesticides to plant parasitic nematodes using tobacco mild green mosaic virus as a nanocarrier</article-title><source>ACS Nano</source><year>2017</year><volume>11</volume><fpage>4719</fpage><lpage>4730</lpage><pub-id pub-id-type="doi">10.1021/acsnano.7b00823</pub-id><pub-id pub-id-type="pmid">28345874</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barone</surname><given-names>PW</given-names></name><etal/></person-group><article-title>Viral contamination in biologic manufacture and implications for emerging therapies</article-title><source>Nat. Biotechnol.</source><year>2020</year><volume>38</volume><fpage>563</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1038/s41587-020-0507-2</pub-id><pub-id pub-id-type="pmid">32341561</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lebel</surname><given-names>M-&#200;</given-names></name><name name-style="western"><surname>Chartrand</surname><given-names>K</given-names></name><name name-style="western"><surname>Leclerc</surname><given-names>D</given-names></name><name name-style="western"><surname>Lamarre</surname><given-names>A</given-names></name></person-group><article-title>Plant viruses as nanoparticle-based vaccines and adjuvants</article-title><source>Vaccines</source><year>2015</year><volume>3</volume><fpage>620</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.3390/vaccines3030620</pub-id><pub-id pub-id-type="pmid">26350598</pub-id><pub-id pub-id-type="pmcid">PMC4586470</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerstetter-Fogle</surname><given-names>A</given-names></name><etal/></person-group><article-title>Plant virus-like particle <italic toggle="yes">in situ</italic> vaccine for intracranial glioma immunotherapy</article-title><source>Cancers</source><year>2019</year><volume>11</volume><fpage>515</fpage><pub-id pub-id-type="doi">10.3390/cancers11040515</pub-id><pub-id pub-id-type="pmid">30974896</pub-id><pub-id pub-id-type="pmcid">PMC6521079</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shukla</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Beiss</surname><given-names>V</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>NF</given-names></name></person-group><article-title>Antibody response against cowpea mosaic viral nanoparticles improves in situ vaccine efficacy in ovarian cancer</article-title><source>ACS Nano</source><year>2020</year><volume>14</volume><fpage>2994</fpage><lpage>3003</lpage><pub-id pub-id-type="doi">10.1021/acsnano.9b07865</pub-id><pub-id pub-id-type="pmid">32133838</pub-id><pub-id pub-id-type="pmcid">PMC8085886</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murray</surname><given-names>AA</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Fiering</surname><given-names>S</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>NF</given-names></name></person-group><article-title><italic toggle="yes">In situ</italic> vaccination with cowpea vs tobacco mosaic virus against melanoma</article-title><source>Mol. Pharm.</source><year>2018</year><volume>15</volume><fpage>3700</fpage><lpage>3716</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00316</pub-id><pub-id pub-id-type="pmid">29798673</pub-id><pub-id pub-id-type="pmcid">PMC6230260</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>S</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>NF</given-names></name></person-group><article-title>Cowpea mosaic virus immunotherapy combined with cyclophosphamide reduces breast cancer tumor burden and inhibits lung metastasis</article-title><source>Adv. Sci.</source><year>2019</year><volume>6</volume><fpage>1802281</fpage><pub-id pub-id-type="doi">10.1002/advs.201802281</pub-id><pub-id pub-id-type="pmcid">PMC6702650</pub-id><pub-id pub-id-type="pmid">31453050</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lizotte</surname><given-names>PH</given-names></name><etal/></person-group><article-title><italic toggle="yes">In situ</italic> vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer</article-title><source>Nat. Nanotechnol.</source><year>2016</year><volume>11</volume><fpage>295</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1038/nnano.2015.292</pub-id><pub-id pub-id-type="pmid">26689376</pub-id><pub-id pub-id-type="pmcid">PMC4777632</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoopes</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Treatment of canine oral melanoma with nanotechnology-based immunotherapy and radiation</article-title><source>Mol. Pharmaceutics.</source><year>2018</year><volume>15</volume><fpage>3717</fpage><lpage>3722</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00126</pub-id><pub-id pub-id-type="pmcid">PMC6296751</pub-id><pub-id pub-id-type="pmid">29613803</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evtushenko</surname><given-names>EA</given-names></name><name name-style="western"><surname>Ryabchevskaya</surname><given-names>EM</given-names></name><name name-style="western"><surname>Nikitin</surname><given-names>NA</given-names></name><name name-style="western"><surname>Atabekov</surname><given-names>JG</given-names></name><name name-style="western"><surname>Karpova</surname><given-names>OV</given-names></name></person-group><article-title>Plant virus particles with various shapes as potential adjuvants</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>10365</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-67023-4</pub-id><pub-id pub-id-type="pmid">32587281</pub-id><pub-id pub-id-type="pmcid">PMC7316779</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shukla</surname><given-names>S</given-names></name><etal/></person-group><article-title>Plant viruses and bacteriophage-based reagents for diagnosis and therapy</article-title><source>Annu. Rev. Virol.</source><year>2020</year><volume>7</volume><fpage>559</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1146/annurev-virology-010720-052252</pub-id><pub-id pub-id-type="pmid">32991265</pub-id><pub-id pub-id-type="pmcid">PMC8018517</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ortega-Rivera</surname><given-names>OA</given-names></name><etal/></person-group><article-title>Trivalent subunit vaccine candidates for COVID-19 and their delivery devices</article-title><source>J. Am. Chem. Soc.</source><year>2021</year><volume>143</volume><fpage>14748</fpage><lpage>14765</lpage><pub-id pub-id-type="doi">10.1021/jacs.1c06600</pub-id><pub-id pub-id-type="pmid">34490778</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>AK</given-names></name><name name-style="western"><surname>Fields</surname><given-names>R</given-names></name><name name-style="western"><surname>McQuestion</surname><given-names>M</given-names></name></person-group><article-title>The future of routine immunization in the developing world: challenges and opportunities</article-title><source>Glob. Health Sci. Pract.</source><year>2014</year><volume>2</volume><fpage>381</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.9745/GHSP-D-14-00137</pub-id><pub-id pub-id-type="pmid">25611473</pub-id><pub-id pub-id-type="pmcid">PMC4307855</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kristensen</surname><given-names>DD</given-names></name><name name-style="western"><surname>Lorenson</surname><given-names>T</given-names></name><name name-style="western"><surname>Bartholomew</surname><given-names>K</given-names></name><name name-style="western"><surname>Villadiego</surname><given-names>S</given-names></name></person-group><article-title>Can thermostable vaccines help address cold-chain challenges? Results from stakeholder interviews in six low- and middle-income countries</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>899</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.01.001</pub-id><pub-id pub-id-type="pmid">26778422</pub-id><pub-id pub-id-type="pmcid">PMC4744085</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaffran</surname><given-names>M</given-names></name><etal/></person-group><article-title>The imperative for stronger vaccine supply and logistics systems</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>B73</fpage><lpage>B80</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.11.036</pub-id><pub-id pub-id-type="pmid">23598495</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eriksson</surname><given-names>P</given-names></name><name name-style="western"><surname>Gessner</surname><given-names>BD</given-names></name><name name-style="western"><surname>Jaillard</surname><given-names>P</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>C</given-names></name><name name-style="western"><surname>Le Gargasson</surname><given-names>JB</given-names></name></person-group><article-title>Vaccine vial monitor availability and use in low- and middle-income countries: a systematic review</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>2155</fpage><lpage>2161</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.102</pub-id><pub-id pub-id-type="pmid">28364924</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halm</surname><given-names>A</given-names></name><etal/></person-group><article-title>Using oral polio vaccine beyond the cold chain: a feasibility study conducted during the national immunization campaign in Mali</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>3467</fpage><lpage>3472</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.02.066</pub-id><pub-id pub-id-type="pmid">20197147</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zipursky</surname><given-names>S</given-names></name><etal/></person-group><article-title>Assessing the potency of oral polio vaccine kept outside of the cold chain during a national immunization campaign in Chad</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>5652</fpage><lpage>5656</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.06.011</pub-id><pub-id pub-id-type="pmid">21699946</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>D</given-names></name><name name-style="western"><surname>Kristensen</surname><given-names>D</given-names></name></person-group><article-title>Opportunities and challenges of developing thermostable vaccines</article-title><source>Expert. Rev. Vaccines</source><year>2009</year><volume>8</volume><fpage>547</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1586/erv.09.20</pub-id><pub-id pub-id-type="pmid">19397412</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngabo</surname><given-names>F</given-names></name><etal/></person-group><article-title>A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>7357</fpage><lpage>7363</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.10.022</pub-id><pub-id pub-id-type="pmid">26519548</pub-id><pub-id pub-id-type="pmcid">PMC5357722</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahamondes</surname><given-names>L</given-names></name><etal/></person-group><article-title>Uniject as a delivery system for the once-a-month injectable contraceptive Cyclofem in Brazil</article-title><source>Contraception</source><year>1996</year><volume>53</volume><fpage>115</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/0010-7824(95)00267-7</pub-id><pub-id pub-id-type="pmid">8838489</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sutanto</surname><given-names>A</given-names></name><name name-style="western"><surname>Suarnawa</surname><given-names>IM</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>CM</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>T</given-names></name><name name-style="western"><surname>Soewarso</surname><given-names>TI</given-names></name></person-group><article-title>Home delivery of heat-stable vaccines in Indonesia: outreach immunization with a prefilled, single-use injection device</article-title><source>Bull. WHO</source><year>1999</year><volume>77</volume><fpage>119</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">10083709</pub-id><pub-id pub-id-type="pmcid">PMC2557593</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dyer</surname><given-names>O</given-names></name></person-group><article-title>Covid-19: many poor countries will see almost no vaccine next year, aid groups warn</article-title><source>BMJ</source><year>2020</year><volume>371</volume><fpage>m4809</fpage><pub-id pub-id-type="doi">10.1136/bmj.m4809</pub-id><pub-id pub-id-type="pmid">33310819</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>JK-C</given-names></name><etal/></person-group><article-title>Realising the value of plant molecular pharming to benefit the poor in developing countries and emerging economies</article-title><source>Plant. Biotechnol. J.</source><year>2013</year><volume>11</volume><fpage>1029</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1111/pbi.12127</pub-id><pub-id pub-id-type="pmid">24119183</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madi</surname><given-names>M</given-names></name><name name-style="western"><surname>Mioulet</surname><given-names>V</given-names></name><name name-style="western"><surname>King</surname><given-names>DP</given-names></name><name name-style="western"><surname>Lomonossoff</surname><given-names>GP</given-names></name><name name-style="western"><surname>Montague</surname><given-names>NP</given-names></name></person-group><article-title>Development of a non-infectious encapsidated positive control RNA for molecular assays to detect foot-and-mouth disease virus</article-title><source>J. Virol. Methods</source><year>2015</year><volume>220</volume><fpage>27</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2015.04.002</pub-id><pub-id pub-id-type="pmid">25864934</pub-id><pub-id pub-id-type="pmcid">PMC4451496</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lin</surname><given-names>T</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>JE</given-names></name><name name-style="western"><surname>Finn</surname><given-names>MG</given-names></name></person-group><article-title>Icosahedral virus particles as addressable nanoscale building blocks</article-title><source>Angew. Chem. Int. Ed.</source><year>2002</year><volume>41</volume><fpage>459</fpage><lpage>462</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1521-3773(20020201)41:3&amp;#x0003c;459::AID-ANIE459&amp;#x0003e;3.0.CO;2-O</pub-id><pub-id pub-id-type="pmid">12491378</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kossover-Smith</surname><given-names>RA</given-names></name><etal/></person-group><article-title>One needle, one syringe, only one time? A survey of physician and nurse knowledge, attitudes, and practices around injection safety</article-title><source>Am. J. Infect. Control.</source><year>2017</year><volume>45</volume><fpage>1018</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1016/j.ajic.2017.04.292</pub-id><pub-id pub-id-type="pmid">28625701</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nir</surname><given-names>Y</given-names></name><name name-style="western"><surname>Paz</surname><given-names>A</given-names></name><name name-style="western"><surname>Sabo</surname><given-names>E</given-names></name><name name-style="western"><surname>Potasman</surname><given-names>I</given-names></name></person-group><article-title>Fear of injections in young adults: prevalence and associations</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2003</year><volume>68</volume><fpage>341</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2003.68.341</pub-id><pub-id pub-id-type="pmid">12685642</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumru</surname><given-names>OS</given-names></name><etal/></person-group><article-title>Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies</article-title><source>Biologicals</source><year>2014</year><volume>42</volume><fpage>237</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2014.05.007</pub-id><pub-id pub-id-type="pmid">24996452</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hageman</surname><given-names>MJ</given-names></name></person-group><article-title>The role of moisture in protein stability</article-title><source>Drug Dev. Ind. Pharm.</source><year>1988</year><volume>14</volume><fpage>2047</fpage><lpage>2070</lpage><pub-id pub-id-type="doi">10.3109/03639048809152002</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulery</surname><given-names>BD</given-names></name><name name-style="western"><surname>Nair</surname><given-names>LS</given-names></name><name name-style="western"><surname>Laurencin</surname><given-names>CT</given-names></name></person-group><article-title>Biomedical applications of biodegradable polymers</article-title><source>J. Polym. Sci. B</source><year>2011</year><volume>49</volume><fpage>832</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1002/polb.22259</pub-id><pub-id pub-id-type="pmcid">PMC3136871</pub-id><pub-id pub-id-type="pmid">21769165</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>PW</given-names></name><etal/></person-group><article-title>Biodegradable viral nanoparticle/polymer implants prepared via melt-processing</article-title><source>ACS Nano</source><year>2017</year><volume>11</volume><fpage>8777</fpage><lpage>8789</lpage><pub-id pub-id-type="doi">10.1021/acsnano.7b02786</pub-id><pub-id pub-id-type="pmid">28902491</pub-id><pub-id pub-id-type="pmcid">PMC5765982</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sullivan</surname><given-names>SP</given-names></name><etal/></person-group><article-title>Dissolving polymer microneedle patches for influenza vaccination</article-title><source>Nat. Med.</source><year>2010</year><volume>16</volume><fpage>915</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1038/nm.2182</pub-id><pub-id pub-id-type="pmid">20639891</pub-id><pub-id pub-id-type="pmcid">PMC2917494</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makadia</surname><given-names>HK</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>SJ</given-names></name></person-group><article-title>Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier</article-title><source>Polymers</source><year>2011</year><volume>3</volume><fpage>1377</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.3390/polym3031377</pub-id><pub-id pub-id-type="pmid">22577513</pub-id><pub-id pub-id-type="pmcid">PMC3347861</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tam</surname><given-names>HH</given-names></name><etal/></person-group><article-title>Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination</article-title><source>Proc. Natl Acad. Sci.</source><year>2016</year><volume>113</volume><fpage>E6639</fpage><lpage>E6648</lpage><pub-id pub-id-type="doi">10.1073/pnas.1606050113</pub-id><pub-id pub-id-type="pmid">27702895</pub-id><pub-id pub-id-type="pmcid">PMC5086995</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapadia</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Extending antigen release from particulate vaccines results in enhanced antitumor immune response</article-title><source>J. Control. Release</source><year>2018</year><volume>269</volume><fpage>393</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.11.020</pub-id><pub-id pub-id-type="pmid">29146244</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walters</surname><given-names>AA</given-names></name><name name-style="western"><surname>Krastev</surname><given-names>C</given-names></name><name name-style="western"><surname>Hill</surname><given-names>AVS</given-names></name><name name-style="western"><surname>Milicic</surname><given-names>A</given-names></name></person-group><article-title>Next generation vaccines: single-dose encapsulated vaccines for improved global immunisation coverage and efficacy</article-title><source>J. Pharm. Pharmacol.</source><year>2015</year><volume>67</volume><fpage>400</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1111/jphp.12367</pub-id><pub-id pub-id-type="pmid">25644530</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohsen</surname><given-names>MO</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>AC</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>M</given-names></name><name name-style="western"><surname>Bachmann</surname><given-names>MF</given-names></name></person-group><article-title>Interaction of viral capsid-derived virus-like particles (VLPs) with the innate immune system</article-title><source>Vaccines</source><year>2018</year><volume>6</volume><fpage>37</fpage><pub-id pub-id-type="doi">10.3390/vaccines6030037</pub-id><pub-id pub-id-type="pmid">30004398</pub-id><pub-id pub-id-type="pmcid">PMC6161069</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>SG</given-names></name><name name-style="western"><surname>Bertholet</surname><given-names>S</given-names></name><name name-style="western"><surname>Coler</surname><given-names>RN</given-names></name><name name-style="western"><surname>Friede</surname><given-names>M</given-names></name></person-group><article-title>New horizons in adjuvants for vaccine development</article-title><source>Trends Immunol.</source><year>2009</year><volume>30</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.it.2008.09.006</pub-id><pub-id pub-id-type="pmid">19059004</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shields</surname><given-names>CW</given-names></name><name name-style="western"><surname>Wang</surname><given-names>LL</given-names></name><name name-style="western"><surname>Evans</surname><given-names>MA</given-names></name><name name-style="western"><surname>Mitragotri</surname><given-names>S</given-names></name></person-group><article-title>Materials for immunotherapy</article-title><source>Adv. Mater.</source><year>2020</year><volume>32</volume><fpage>1901633</fpage><pub-id pub-id-type="doi">10.1002/adma.201901633</pub-id><pub-id pub-id-type="pmid">31250498</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>KS</given-names></name></person-group><article-title>Biomaterials as vaccine adjuvants</article-title><source>Biotechnol. Progress.</source><year>2008</year><volume>24</volume><fpage>807</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1002/btpr.10</pub-id><pub-id pub-id-type="pmid">19194892</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>R</given-names></name><name name-style="western"><surname>Shah</surname><given-names>NH</given-names></name><name name-style="western"><surname>Malick</surname><given-names>AW</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>CT</given-names></name></person-group><article-title>Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches</article-title><source>Drug Dev. Ind. Pharm.</source><year>1998</year><volume>24</volume><fpage>703</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.3109/03639049809082719</pub-id><pub-id pub-id-type="pmid">9876519</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>N</given-names></name><name name-style="western"><surname>Langer</surname><given-names>RS</given-names></name><name name-style="western"><surname>Domb</surname><given-names>AJ</given-names></name></person-group><article-title>Polyanhydrides: an overview</article-title><source>Adv. Drug Deliv. Rev.</source><year>2002</year><volume>54</volume><fpage>889</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(02)00050-9</pub-id><pub-id pub-id-type="pmid">12384314</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>JL</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>CH</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>MK</given-names></name></person-group><article-title>The mechanism of PLA microparticle formation by water-in-oil-in-water solvent evaporation method</article-title><source>J. Microencapsul.</source><year>2002</year><volume>19</volume><fpage>333</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1080/02652040110105373</pub-id><pub-id pub-id-type="pmid">12022499</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van de Weert</surname><given-names>M</given-names></name><name name-style="western"><surname>Hennink</surname><given-names>WE</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W</given-names></name></person-group><article-title>Protein instability in poly(lactic-co-glycolic acid) microparticles</article-title><source>Pharm. Res.</source><year>2000</year><volume>17</volume><fpage>1159</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1023/A:1026498209874</pub-id><pub-id pub-id-type="pmid">11145219</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sah</surname><given-names>H</given-names></name></person-group><article-title>Protein instability toward organic solvent/water emulsification: implications for protein microencapsulation into microspheres</article-title><source>PDA J. Pharm. Sci. Technol.</source><year>1999</year><volume>53</volume><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">10343502</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Illum</surname><given-names>L</given-names></name><name name-style="western"><surname>Jabbal-Gill</surname><given-names>I</given-names></name><name name-style="western"><surname>Hinchcliffe</surname><given-names>M</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>AN</given-names></name><name name-style="western"><surname>Davis</surname><given-names>SS</given-names></name></person-group><article-title>Chitosan as a novel nasal delivery system for vaccines</article-title><source>Adv. Drug Deliv. Rev.</source><year>2001</year><volume>51</volume><fpage>81</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(01)00171-5</pub-id><pub-id pub-id-type="pmid">11516781</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soane</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Evaluation of the clearance characteristics of bioadhesive systems in humans</article-title><source>Int. J. Pharm.</source><year>1999</year><volume>178</volume><fpage>55</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/S0378-5173(98)00367-6</pub-id><pub-id pub-id-type="pmid">10205625</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sl&#252;tter</surname><given-names>B</given-names></name><name name-style="western"><surname>Hagenaars</surname><given-names>N</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W</given-names></name></person-group><article-title>Rational design of nasal vaccines</article-title><source>J. Drug Target.</source><year>2008</year><volume>16</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1080/10611860701637966</pub-id><pub-id pub-id-type="pmid">18172815</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name></person-group><article-title>Recent advances of microneedles for biomedical applications: drug delivery and beyond</article-title><source>Acta Pharm. Sin. B</source><year>2019</year><volume>9</volume><fpage>469</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2019.03.007</pub-id><pub-id pub-id-type="pmid">31193810</pub-id><pub-id pub-id-type="pmcid">PMC6543086</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nestle</surname><given-names>FO</given-names></name><name name-style="western"><surname>Meglio</surname><given-names>PD</given-names></name><name name-style="western"><surname>Qin</surname><given-names>J-Z</given-names></name><name name-style="western"><surname>Nickoloff</surname><given-names>BJ</given-names></name></person-group><article-title>Skin immune sentinels in health and disease</article-title><source>Nat. Rev. Immunol.</source><year>2009</year><volume>9</volume><fpage>679</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1038/nri2622</pub-id><pub-id pub-id-type="pmid">19763149</pub-id><pub-id pub-id-type="pmcid">PMC2947825</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menon</surname><given-names>I</given-names></name><etal/></person-group><article-title>Microneedles: a new generation vaccine delivery system</article-title><source>Micromachines</source><year>2021</year><volume>12</volume><fpage>435</fpage><pub-id pub-id-type="doi">10.3390/mi12040435</pub-id><pub-id pub-id-type="pmid">33919925</pub-id><pub-id pub-id-type="pmcid">PMC8070939</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>M</given-names></name><name name-style="western"><surname>Shan</surname><given-names>H</given-names></name><name name-style="western"><surname>Tong</surname><given-names>C</given-names></name></person-group><article-title>Microneedle patches as drug and vaccine delivery platform</article-title><source>Curr. Med. Chem.</source><year>2017</year><volume>24</volume><fpage>2413</fpage><lpage>2422</lpage><pub-id pub-id-type="doi">10.2174/0929867324666170526124053</pub-id><pub-id pub-id-type="pmid">28552053</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y-C</given-names></name><name name-style="western"><surname>Quan</surname><given-names>F-S</given-names></name><name name-style="western"><surname>Compans</surname><given-names>RW</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S-M</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>MR</given-names></name></person-group><article-title>Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity</article-title><source>J. Control. Release</source><year>2010</year><volume>142</volume><fpage>187</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2009.10.013</pub-id><pub-id pub-id-type="pmid">19840825</pub-id><pub-id pub-id-type="pmcid">PMC2823933</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeMuth</surname><given-names>PC</given-names></name><name name-style="western"><surname>Moon</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Suh</surname><given-names>H</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>PT</given-names></name><name name-style="western"><surname>Irvine</surname><given-names>DJ</given-names></name></person-group><article-title>Releasable layer-by-layer assembly of stabilized lipid nanocapsules on microneedles for enhanced transcutaneous vaccine delivery</article-title><source>ACS Nano</source><year>2012</year><volume>6</volume><fpage>8041</fpage><lpage>8051</lpage><pub-id pub-id-type="doi">10.1021/nn302639r</pub-id><pub-id pub-id-type="pmid">22920601</pub-id><pub-id pub-id-type="pmcid">PMC3475723</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gill</surname><given-names>HS</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>MR</given-names></name></person-group><article-title>Coated microneedles for transdermal delivery</article-title><source>J. Control. Release</source><year>2007</year><volume>117</volume><fpage>227</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2006.10.017</pub-id><pub-id pub-id-type="pmid">17169459</pub-id><pub-id pub-id-type="pmcid">PMC1853346</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>H-J</given-names></name><etal/></person-group><article-title>Stability of whole inactivated influenza virus vaccine during coating onto metal microneedles</article-title><source>J. Control. Release</source><year>2013</year><volume>166</volume><fpage>159</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2012.12.002</pub-id><pub-id pub-id-type="pmid">23246470</pub-id><pub-id pub-id-type="pmcid">PMC3578180</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrianov</surname><given-names>AK</given-names></name><name name-style="western"><surname>Mutwiri</surname><given-names>G</given-names></name></person-group><article-title>Intradermal immunization using coated microneedles containing an immunoadjuvant</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>4355</fpage><lpage>4360</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.09.062</pub-id><pub-id pub-id-type="pmid">22682291</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donnelly</surname><given-names>RF</given-names></name><name name-style="western"><surname>Raj Singh</surname><given-names>TR</given-names></name><name name-style="western"><surname>Woolfson</surname><given-names>AD</given-names></name></person-group><article-title>Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety</article-title><source>Drug Deliv.</source><year>2010</year><volume>17</volume><fpage>187</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.3109/10717541003667798</pub-id><pub-id pub-id-type="pmid">20297904</pub-id><pub-id pub-id-type="pmcid">PMC2906704</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M-C</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S-F</given-names></name><name name-style="western"><surname>Lai</surname><given-names>K-Y</given-names></name><name name-style="western"><surname>Ling</surname><given-names>M-H</given-names></name></person-group><article-title>Fully embeddable chitosan microneedles as a sustained release depot for intradermal vaccination</article-title><source>Biomaterials</source><year>2013</year><volume>34</volume><fpage>3077</fpage><lpage>3086</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.12.041</pub-id><pub-id pub-id-type="pmid">23369214</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>X</given-names></name><etal/></person-group><article-title>Dissolving and biodegradable microneedle technologies for transdermal sustained delivery of drug and vaccine</article-title><source>Drug Des. Devel. Ther.</source><year>2013</year><volume>7</volume><fpage>945</fpage><lpage>952</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S44401</pub-id><pub-id pub-id-type="pmcid">PMC3771849</pub-id><pub-id pub-id-type="pmid">24039404</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bachy</surname><given-names>V</given-names></name><etal/></person-group><article-title>Langerin negative dendritic cells promote potent CD8<sup>+</sup> T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>3041</fpage><lpage>3046</lpage><pub-id pub-id-type="doi">10.1073/pnas.1214449110</pub-id><pub-id pub-id-type="pmid">23386724</pub-id><pub-id pub-id-type="pmcid">PMC3581957</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edens</surname><given-names>C</given-names></name><name name-style="western"><surname>Collins</surname><given-names>ML</given-names></name><name name-style="western"><surname>Goodson</surname><given-names>JL</given-names></name><name name-style="western"><surname>Rota</surname><given-names>PA</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>MR</given-names></name></person-group><article-title>A microneedle patch containing measles vaccine is immunogenic in non-human primates</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>4712</fpage><lpage>4718</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.02.074</pub-id><pub-id pub-id-type="pmid">25770786</pub-id><pub-id pub-id-type="pmcid">PMC4554796</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J-H</given-names></name><name name-style="western"><surname>Allen</surname><given-names>MG</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>MR</given-names></name></person-group><article-title>Polymer microneedles for controlled-release drug delivery</article-title><source>Pharm. Res.</source><year>2006</year><volume>23</volume><fpage>1008</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.1007/s11095-006-0028-9</pub-id><pub-id pub-id-type="pmid">16715391</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carter</surname><given-names>D</given-names></name><etal/></person-group><article-title>The adjuvant GLA-AF enhances human intradermal vaccine responses</article-title><source>Sci. Adv.</source><year>2018</year><volume>4</volume><fpage>eaas9930</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aas9930</pub-id><pub-id pub-id-type="pmid">30221194</pub-id><pub-id pub-id-type="pmcid">PMC6136895</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boone</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Active microneedle administration of plant virus nanoparticles for cancer in situ vaccination improves immunotherapeutic efficacy</article-title><source>ACS Appl. Nano Mater.</source><year>2020</year><volume>3</volume><fpage>8037</fpage><lpage>8051</lpage><pub-id pub-id-type="doi">10.1021/acsanm.0c01506</pub-id><pub-id pub-id-type="pmid">33969278</pub-id><pub-id pub-id-type="pmcid">PMC8101548</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bamogo</surname><given-names>PKA</given-names></name><etal/></person-group><article-title>Virus-based pharmaceutical production in plants: an opportunity to reduce health problems in Africa</article-title><source>Virol. J.</source><year>2019</year><volume>16</volume><fpage>167</fpage><pub-id pub-id-type="doi">10.1186/s12985-019-1263-0</pub-id><pub-id pub-id-type="pmid">31888686</pub-id><pub-id pub-id-type="pmcid">PMC6937724</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNulty</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Molecular pharming to support human life on the Moon, Mars, and beyond</article-title><source>Crit. Rev. Biotechnol.</source><year>2020</year><volume>41</volume><fpage>849</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1080/07388551.2021.1888070</pub-id><pub-id pub-id-type="pmid">33715563</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><mixed-citation publication-type="other">Davies, R., Hardern, I. &amp; Overman, R. A history of recombinant protein technology in small molecule drug discovery. <italic toggle="yes">Eur. Pharm. Rev.</italic><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.europeanpharmaceuticalreview.com/article/27775/history-recombinant-protein-technology-small-molecule-drug-discovery/">https://www.europeanpharmaceuticalreview.com/article/27775/history-recombinant-protein-technology-small-molecule-drug-discovery/</ext-link> (2014).</mixed-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lico</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Santi</surname><given-names>L</given-names></name></person-group><article-title>Viral vectors for production of recombinant proteins in plants</article-title><source>J. Cell Physiol.</source><year>2008</year><volume>216</volume><fpage>366</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1002/jcp.21423</pub-id><pub-id pub-id-type="pmid">18330886</pub-id><pub-id pub-id-type="pmcid">PMC7166642</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Platis</surname><given-names>D</given-names></name><name name-style="western"><surname>Labrou</surname><given-names>NE</given-names></name></person-group><article-title>Development of an aqueous two-phase partitioning system for fractionating therapeutic proteins from tobacco extract</article-title><source>J. Chromatogr. A.</source><year>2006</year><volume>1128</volume><fpage>114</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.chroma.2006.06.047</pub-id><pub-id pub-id-type="pmid">16828788</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gen&#231;da&#287;</surname><given-names>E</given-names></name><name name-style="western"><surname>G&#246;rg&#252;&#231;</surname><given-names>A</given-names></name><name name-style="western"><surname>Y&#305;lmaz</surname><given-names>FM</given-names></name></person-group><article-title>Recent advances in the recovery techniques of plant-based proteins from agro-industrial by-products</article-title><source>Food Rev. Int.</source><year>2021</year><volume>37</volume><fpage>447</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1080/87559129.2019.1709203</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>R</given-names></name><name name-style="western"><surname>Drossard</surname><given-names>J</given-names></name><name name-style="western"><surname>Commandeur</surname><given-names>U</given-names></name><name name-style="western"><surname>Schillberg</surname><given-names>S</given-names></name><name name-style="western"><surname>Emans</surname><given-names>N</given-names></name></person-group><article-title>Towards molecular farming in the future: moving from diagnostic protein and antibody production in microbes to plants</article-title><source>Biotechnol. Appl. Biochem.</source><year>1999</year><volume>30</volume><fpage>101</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">10512787</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daniell</surname><given-names>H</given-names></name><name name-style="western"><surname>Streatfield</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Wycoff</surname><given-names>K</given-names></name></person-group><article-title>Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants</article-title><source>Trends Plant. Sci.</source><year>2001</year><volume>6</volume><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/S1360-1385(01)01922-7</pub-id><pub-id pub-id-type="pmid">11335175</pub-id><pub-id pub-id-type="pmcid">PMC5496653</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><mixed-citation publication-type="other">Sahai, A., Shahzad, A. &amp; Shahid, M. in <italic toggle="yes">Recent Trends in Biotechnology and Therapeutic Applications of Medicinal Plants</italic> (eds Shahid, M., Shahzad, A., Malik, A., Sahai, A.) 225&#8211;252 (Springer Netherlands, 2013).</mixed-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berardi</surname><given-names>A</given-names></name><name name-style="western"><surname>Evans</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Bombelli</surname><given-names>FB</given-names></name><name name-style="western"><surname>Lomonossoff</surname><given-names>GP</given-names></name></person-group><article-title>Stability of plant virus-based nanocarriers in gastrointestinal fluids</article-title><source>Nanoscale</source><year>2018</year><volume>10</volume><fpage>1667</fpage><lpage>1679</lpage><pub-id pub-id-type="doi">10.1039/C7NR07182E</pub-id><pub-id pub-id-type="pmid">29231944</pub-id><pub-id pub-id-type="pmcid">PMC5804478</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><etal/></person-group><article-title>Rational design of thermostable vaccines by engineered peptide-induced virus self-biomineralization under physiological conditions</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>7619</fpage><lpage>7624</lpage><pub-id pub-id-type="doi">10.1073/pnas.1300233110</pub-id><pub-id pub-id-type="pmid">23589862</pub-id><pub-id pub-id-type="pmcid">PMC3651461</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiggan</surname><given-names>O</given-names></name><etal/></person-group><article-title>Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>7456</fpage><lpage>7462</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.07.054</pub-id><pub-id pub-id-type="pmid">21803103</pub-id><pub-id pub-id-type="pmcid">PMC3186865</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lievano</surname><given-names>F</given-names></name><etal/></person-group><article-title>Measles, mumps, and rubella virus vaccine (M-M-R<sup>TM</sup>II): a review of 32 years of clinical and postmarketing experience</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>6918</fpage><lpage>6926</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.08.057</pub-id><pub-id pub-id-type="pmid">22959986</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Herck</surname><given-names>K</given-names></name><name name-style="western"><surname>Van Damme</surname><given-names>P</given-names></name></person-group><article-title>Prevention of hepatitis A by Havrix: a review</article-title><source>Expert Rev. Vaccines</source><year>2005</year><volume>4</volume><fpage>459</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1586/14760584.4.4.459</pub-id><pub-id pub-id-type="pmid">16117704</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Damme</surname><given-names>P</given-names></name><etal/></person-group><article-title>Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults</article-title><source>Hum. Vaccin</source><year>2009</year><volume>5</volume><fpage>92</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.4161/hv.5.2.6587</pub-id><pub-id pub-id-type="pmid">18690015</pub-id></element-citation></ref><ref id="CR166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Du</surname><given-names>J</given-names></name></person-group><article-title>Human papillomavirus vaccines: an updated review</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><fpage>391</fpage><pub-id pub-id-type="doi">10.3390/vaccines8030391</pub-id><pub-id pub-id-type="pmid">32708759</pub-id><pub-id pub-id-type="pmcid">PMC7565290</pub-id></element-citation></ref><ref id="CR167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollet</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W-H</given-names></name><name name-style="western"><surname>Strych</surname><given-names>U</given-names></name></person-group><article-title>Recombinant protein vaccines, a proven approach against coronavirus pandemics</article-title><source>Adv. Drug Deliv. Rev.</source><year>2021</year><volume>170</volume><fpage>71</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.01.001</pub-id><pub-id pub-id-type="pmid">33421475</pub-id><pub-id pub-id-type="pmcid">PMC7788321</pub-id></element-citation></ref><ref id="CR168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhuyan</surname><given-names>PK</given-names></name><etal/></person-group><article-title>Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL</article-title><source>Hum. Vaccin. Immunother.</source><year>2020</year><volume>17</volume><fpage>1288</fpage><lpage>1293</lpage><pub-id pub-id-type="doi">10.1080/21645515.2020.1823778</pub-id><pub-id pub-id-type="pmid">33175656</pub-id><pub-id pub-id-type="pmcid">PMC8078703</pub-id></element-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolf</surname><given-names>J</given-names></name><etal/></person-group><article-title>Development of pandemic vaccines: ERVEBO case study</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><fpage>190</fpage><pub-id pub-id-type="doi">10.3390/vaccines9030190</pub-id><pub-id pub-id-type="pmid">33668698</pub-id><pub-id pub-id-type="pmcid">PMC7996233</pub-id></element-citation></ref><ref id="CR170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tregoning</surname><given-names>JS</given-names></name></person-group><article-title>First human efficacy study of a plant-derived influenza vaccine</article-title><source>Lancet</source><year>2020</year><volume>396</volume><fpage>1464</fpage><lpage>1465</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32010-9</pub-id><pub-id pub-id-type="pmid">33065033</pub-id><pub-id pub-id-type="pmcid">PMC7553753</pub-id></element-citation></ref><ref id="CR171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name></person-group><article-title>Transformation of HBsAg (hepatitis B surface antigen) gene into tomato mediated by <italic toggle="yes">Agrobacterium tumefaciens</italic></article-title><source>Czech J. Genet. Plant. Breed.</source><year>2011</year><volume>47</volume><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.17221/5/2011-CJGPB</pub-id></element-citation></ref><ref id="CR172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosales-Mendoza</surname><given-names>S</given-names></name><etal/></person-group><article-title>Expression of <italic toggle="yes">Escherichia coli</italic> heat-labile enterotoxin b subunit (LTB) in carrot (<italic toggle="yes">Daucus carota</italic> L.)</article-title><source>Plant. Cell Rep.</source><year>2007</year><volume>26</volume><fpage>969</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1007/s00299-007-0310-2</pub-id><pub-id pub-id-type="pmid">17310334</pub-id></element-citation></ref><ref id="CR173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y-Z</given-names></name><etal/></person-group><article-title>Oral immunization with rotavirus VP7 expressed in transgenic potatoes induced high titers of mucosal neutralizing IgA</article-title><source>Virology</source><year>2003</year><volume>313</volume><fpage>337</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1016/S0042-6822(03)00280-0</pub-id><pub-id pub-id-type="pmid">12954202</pub-id></element-citation></ref><ref id="CR174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phoolcharoen</surname><given-names>W</given-names></name><etal/></person-group><article-title>Expression of an immunogenic Ebola immune complex in <italic toggle="yes">Nicotiana benthamiana</italic></article-title><source>Plant. Biotechnol. J.</source><year>2011</year><volume>9</volume><fpage>807</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1111/j.1467-7652.2011.00593.x</pub-id><pub-id pub-id-type="pmid">21281425</pub-id><pub-id pub-id-type="pmcid">PMC4022790</pub-id></element-citation></ref><ref id="CR175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>High expression of foot-and-mouth disease virus structural protein VP1 in tobacco chloroplasts</article-title><source>Plant. Cell Rep.</source><year>2006</year><volume>25</volume><fpage>329</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1007/s00299-005-0074-5</pub-id><pub-id pub-id-type="pmid">16320056</pub-id></element-citation></ref><ref id="CR176"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>RM</given-names></name><etal/></person-group><article-title>A Plant-Produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against <italic toggle="yes">Plasmodium falciparum</italic> in immunized mice</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>e79538</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0079538</pub-id><pub-id pub-id-type="pmid">24260245</pub-id><pub-id pub-id-type="pmcid">PMC3832600</pub-id></element-citation></ref><ref id="CR177"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name></person-group><article-title>Bioprocessing of plant-derived virus-like particles of Norwalk virus capsid protein under current good manufacture practice regulations</article-title><source>Plant. Cell Rep.</source><year>2012</year><volume>31</volume><fpage>573</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1007/s00299-011-1196-6</pub-id><pub-id pub-id-type="pmid">22134876</pub-id><pub-id pub-id-type="pmcid">PMC3278561</pub-id></element-citation></ref><ref id="CR178"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>M-Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M-S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T-G</given-names></name></person-group><article-title>Expression of dengue virus E glycoprotein domain III in non-nicotine transgenic tobacco plants</article-title><source>Biotechnol. Bioproc. E</source><year>2009</year><volume>14</volume><fpage>725</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1007/s12257-009-3011-6</pub-id></element-citation></ref><ref id="CR179"><label>179.</label><mixed-citation publication-type="other">US National Library of Medicine. <italic toggle="yes">ClinicalTrials.gov</italic><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04450004">https://clinicaltrials.gov/ct2/show/NCT04450004</ext-link> (2020).</mixed-citation></ref><ref id="CR180"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ceballo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>High accumulation in tobacco seeds of hemagglutinin antigen from avian (H5N1) influenza</article-title><source>Transgenic Res.</source><year>2017</year><volume>26</volume><fpage>775</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1007/s11248-017-0047-9</pub-id><pub-id pub-id-type="pmid">28986672</pub-id></element-citation></ref><ref id="CR181"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olinger</surname><given-names>GG</given-names></name><etal/></person-group><article-title>Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>18030</fpage><lpage>18035</lpage><pub-id pub-id-type="doi">10.1073/pnas.1213709109</pub-id><pub-id pub-id-type="pmid">23071322</pub-id><pub-id pub-id-type="pmcid">PMC3497800</pub-id></element-citation></ref><ref id="CR182"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Penney</surname><given-names>CA</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>DR</given-names></name><name name-style="western"><surname>Deen</surname><given-names>SS</given-names></name><name name-style="western"><surname>Walmsley</surname><given-names>AM</given-names></name></person-group><article-title>Plant-made vaccines in support of the millennium development goals</article-title><source>Plant Cell Rep.</source><year>2011</year><volume>30</volume><fpage>789</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1007/s00299-010-0995-5</pub-id><pub-id pub-id-type="pmid">21243362</pub-id><pub-id pub-id-type="pmcid">PMC3075396</pub-id></element-citation></ref><ref id="CR183"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atsmon</surname><given-names>J</given-names></name><etal/></person-group><article-title>Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R</article-title><source>Toxicol. Appl. Pharmacol.</source><year>2015</year><volume>287</volume><fpage>202</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/j.taap.2015.06.004</pub-id><pub-id pub-id-type="pmid">26051873</pub-id></element-citation></ref><ref id="CR184"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bethell</surname><given-names>DR</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name></person-group><article-title>Recombinant human lactoferrin treatment for global health issues: iron deficiency and acute diarrhea</article-title><source>Biometals</source><year>2004</year><volume>17</volume><fpage>337</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1023/B:BIOM.0000027714.56331.b8</pub-id><pub-id pub-id-type="pmid">15222487</pub-id></element-citation></ref><ref id="CR185"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shanmugaraj</surname><given-names>B</given-names></name><name name-style="western"><surname>Rattanapisit</surname><given-names>K</given-names></name><name name-style="western"><surname>Manopwisedjaroen</surname><given-names>S</given-names></name><name name-style="western"><surname>Thitithanyanont</surname><given-names>A</given-names></name><name name-style="western"><surname>Phoolcharoen</surname><given-names>W</given-names></name></person-group><article-title>Monoclonal antibodies B38 and H4 produced in <italic toggle="yes">Nicotiana benthamiana</italic> neutralize SARS-CoV-2 in vitro</article-title><source>Front. Plant Sci.</source><year>2020</year><volume>11</volume><fpage>589995</fpage><pub-id pub-id-type="doi">10.3389/fpls.2020.589995</pub-id><pub-id pub-id-type="pmid">33329653</pub-id><pub-id pub-id-type="pmcid">PMC7728718</pub-id></element-citation></ref><ref id="CR186"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rattanapisit</surname><given-names>K</given-names></name><etal/></person-group><article-title>Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in <italic toggle="yes">Nicotiana benthamiana</italic></article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>17698</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-74904-1</pub-id><pub-id pub-id-type="pmid">33077899</pub-id><pub-id pub-id-type="pmcid">PMC7573609</pub-id></element-citation></ref><ref id="CR187"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tekoah</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Large-scale production of pharmaceutical proteins in plant cell culture &#8212; the protalix experience</article-title><source>Plant. Biotechnol. J.</source><year>2015</year><volume>13</volume><fpage>1199</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1111/pbi.12428</pub-id><pub-id pub-id-type="pmid">26102075</pub-id></element-citation></ref><ref id="CR188"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perea Arango</surname><given-names>I</given-names></name><etal/></person-group><article-title>Expression of the rabies virus nucleoprotein in plants at high-levels and evaluation of immune responses in mice</article-title><source>Plant. Cell Rep.</source><year>2008</year><volume>27</volume><fpage>677</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1007/s00299-007-0324-9</pub-id><pub-id pub-id-type="pmid">18270708</pub-id></element-citation></ref><ref id="CR189"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woodruff</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hutmacher</surname><given-names>DW</given-names></name></person-group><article-title>The return of a forgotten polymer &#8212; polycaprolactone in the 21st century</article-title><source>Prog. Polym. Sci.</source><year>2010</year><volume>35</volume><fpage>1217</fpage><lpage>1256</lpage><pub-id pub-id-type="doi">10.1016/j.progpolymsci.2010.04.002</pub-id></element-citation></ref><ref id="CR190"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>da Silva</surname><given-names>D</given-names></name><etal/></person-group><article-title>Biocompatibility, biodegradation and excretion of polylactic acid (PLA) in medical implants and theranostic systems</article-title><source>Chem. Eng. J.</source><year>2018</year><volume>340</volume><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.cej.2018.01.010</pub-id><pub-id pub-id-type="pmid">31384170</pub-id><pub-id pub-id-type="pmcid">PMC6682490</pub-id></element-citation></ref><ref id="CR191"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teasdale</surname><given-names>I</given-names></name><name name-style="western"><surname>Br&#252;ggemann</surname><given-names>O</given-names></name></person-group><article-title>Polyphosphazenes: multifunctional, biodegradable vehicles for drug and gene delivery</article-title><source>Polymers</source><year>2013</year><volume>5</volume><fpage>161</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.3390/polym5010161</pub-id><pub-id pub-id-type="pmid">24729871</pub-id><pub-id pub-id-type="pmcid">PMC3982046</pub-id></element-citation></ref><ref id="CR192"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fakhari</surname><given-names>A</given-names></name><name name-style="western"><surname>Berkland</surname><given-names>C</given-names></name></person-group><article-title>Applications and emerging trends of hyaluronic acid in tissue engineering, as a dermal filler and in osteoarthritis treatment</article-title><source>Acta Biomater.</source><year>2013</year><volume>9</volume><fpage>7081</fpage><lpage>7092</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2013.03.005</pub-id><pub-id pub-id-type="pmid">23507088</pub-id><pub-id pub-id-type="pmcid">PMC3669638</pub-id></element-citation></ref><ref id="CR193"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klotz</surname><given-names>U</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>H</given-names></name></person-group><article-title>Clinical pharmacokinetic considerations in the use of plasma expanders</article-title><source>Clin. Pharmacokinet.</source><year>1987</year><volume>12</volume><fpage>123</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.2165/00003088-198712020-00003</pub-id><pub-id pub-id-type="pmid">2435442</pub-id></element-citation></ref><ref id="CR194"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>KY</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>DJ</given-names></name></person-group><article-title>Alginate: properties and biomedical applications</article-title><source>Prog. Polym. Sci.</source><year>2012</year><volume>37</volume><fpage>106</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.progpolymsci.2011.06.003</pub-id><pub-id pub-id-type="pmid">22125349</pub-id><pub-id pub-id-type="pmcid">PMC3223967</pub-id></element-citation></ref><ref id="CR195"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>LY</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S-O</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>MR</given-names></name></person-group><article-title>Fabrication of dissolving polymer microneedles for controlled drug encapsulation and delivery: bubble and pedestal microneedle designs</article-title><source>J. Pharm. Sci.</source><year>2010</year><volume>99</volume><fpage>4228</fpage><lpage>4238</lpage><pub-id pub-id-type="doi">10.1002/jps.22140</pub-id><pub-id pub-id-type="pmid">20737630</pub-id></element-citation></ref><ref id="CR196"><label>196.</label><mixed-citation publication-type="other">Low, L.-Y. et al. in <italic toggle="yes">New Visions in Plant Science</italic> (ed. Celik, O) Ch. 3 (InTechOpen, 2018).</mixed-citation></ref><ref id="CR197"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ochoa-Villarreal</surname><given-names>M</given-names></name><etal/></person-group><article-title>Plant cell culture strategies for the production of natural products</article-title><source>BMB Rep.</source><year>2016</year><volume>49</volume><fpage>149</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.5483/BMBRep.2016.49.3.264</pub-id><pub-id pub-id-type="pmid">26698871</pub-id><pub-id pub-id-type="pmcid">PMC4915229</pub-id></element-citation></ref><ref id="CR198"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torti</surname><given-names>S</given-names></name><etal/></person-group><article-title>Transient reprogramming of crop plants for agronomic performance</article-title><source>Nat. Plants</source><year>2021</year><volume>7</volume><fpage>159</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1038/s41477-021-00851-y</pub-id><pub-id pub-id-type="pmid">33594264</pub-id></element-citation></ref><ref id="CR199"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clough</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Bent</surname><given-names>AF</given-names></name></person-group><article-title>Floral dip: a simplified method for <italic toggle="yes">Agrobacterium</italic>-mediated transformation of <italic toggle="yes">Arabidopsis thaliana</italic></article-title><source>Plant J.</source><year>1998</year><volume>16</volume><fpage>735</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1046/j.1365-313x.1998.00343.x</pub-id><pub-id pub-id-type="pmid">10069079</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>